MULTIVARIATE ANALYSIS OF DENGUE IN A TERTIARY CARE HOSPITAL

Dissertation submitted in
Partial Fulfillment of the regulations required for the award of

M.D DEGREE

In

Microbiology – Branch IV

THE TAMILNADU DR.M.G.R MEDICAL UNIVERSITY,
CHENNAI – 600 032.

April 2013
DECLARATION

I Dr P. Malini solemnly declare that the dissertation entitled “Multivariate Analysis of Dengue in a Tertiary Care Hospital” was done by me at Coimbatore Medical College, Coimbatore during the period September 2011 to August 2012 under the supervision and guidance of Dr. K. RAJENDRAN BSc, M.D., Professor and HOD Department of Microbiology Coimbatore Medical College Coimbatore – 14.

This dissertation is submitted to the TamilNadu Dr. M.G.R Medical University, Chennai towards the partial fulfillment of the requirement for the award of M.D Degree (Branch – IV) in Microbiology to be held in April 2013.

I have not submitted this dissertation on any previous occasion to any university for the award of any degree.

Dr. P. Malini

Place:

Date:
CERTIFICATE

This is to certify that the dissertation entitled “MULTIVARIATE ANALYSIS OF DENGUE IN A TERTIARY CARE HOSPITAL” is a bonafide work done by Dr.P.Malini, post graduate student in the Department of Microbiology, under the supervision of Dr.K.RAJENDRAN B.Sc, M.D., Professor & Head Department of Microbiology, Coimbatore Medical College, Coimbatore, in fulfillment of the regulation of the Tamil Nadu Dr.M.G.R Medical University, towards the award of M.D Degree (Branch – IV) in Microbiology.

DR.R.VIMALA M.D.,
Dean
Coimbatore Medical College
Coimbatore – 14

DR.K.RAJENDRAN B.Sc,M.D.,
Professor & Head
Department of Microbiology
Coimbatore Medical College
Coimbatore - 14
Name of the Candidate : DR. P. MALINI
Course : M.D. MICROBIOLOGY
Period of Study : SEPTEMBER 2011 - AUGUST 2012
College : COIMBATORE MEDICAL COLLEGE
Dissertation Topic : MULTIVARIATE ANALYSIS OF DENGUE IN A TERTIARY CARE HOSPITAL

The Ethics Committee, Coimbatore Medical College has decided to inform that your Dissertation Proposal is accepted / Not accepted and you are permitted / Not permitted to proceed with the above Study.

Coimbatore - 14.
Date : 23.9.11

Secretary
Ethics Committee
ACKNOWLEDGEMENT

I am grateful to the Dean, Dr. R. Vimala M.D., Coimbatore Medical College and Hospital, for permitting me to carry out this study.

I thank Dr. Lalitha M.D., Vice Principal, Coimbatore Medical College for her encouragement in completing this study.

I wish to place on the records my deep sense of gratitude and sincere thanks to Professor & HOD Dr. K. Rajendran BSc, M.D., Department of Microbiology for his precious guidance and valuable suggestions given throughout the study.

I express my sincere thanks to our Associate Professors Dr. V. Sadhiqua M.D, D.G.O., Dr V. Dhanasekharan M.D, D.C.H, Dr. N. Mythili M.D., Department of Microbiology, Coimbatore Medical College.

I would like to place my thanks to our Assistant Professors Dr. N. Bharathi Santhose M.D., Dr S. Deepa M.D., Dr. B. Padmini M.D., Dr. R. Radhika M.D., for their constant help, guidance and encouragement given to me throughout this study.

I express my immense thanks to Prof. Dr. Veerakesari, M.D., Professor and Head of the Department, Department of Medicine and Dr. Neelakandan M.D., Professor and Head of the Department of Paediatrics for their kind cooperation in selection of cases, collection of specimens and datas.

I am thankful to my colleagues Dr. Lokeshwari, Dr. Aruna, Dr. Ashwini, Dr. Bhuvaneshwari, Dr. Kokilapriya, Dr. Deepa, Dr. Swaathy, Dr. Vijayashree, Dr. Sathyapriya, Dr. M. Preethi, Dr. Shanthi.
At last but not the least, I extend my thanks to all staff members, Department of Microbiology for giving full cooperation and timely help in carrying out this study.

I would like to thank the Institutional Ethical Committee for approving my study.

I thank my family members for their immense help and support throughout this study. Finally I thank the Almighty for his blessings in every moment in my life.
MULTIVARIATE ANALYSIS OF DENGUE IN A TERTIARY CARE HOSPITAL

Dissertation submitted in

Partial Fulfillment of the regulations required for the award of

M.D DEGREE

In

Microbiology – Branch IV

THE TAMILNADU DR.M.G.R MEDICAL UNIVERSITY,

CHENNAI – 600 032
Welcome to your new class homepage! From the class homepage you can see all your assignments for your class, view additional assignment information, submit your work, and access feedback for your papers.

Hover on any item in the class homepage for more information.

This is your class homepage. To submit to an assignment click on the "Submit" button to the right of the assignment name. If the Submit button is grayed out, no submissions can be made to the assignment. If resubmissions are allowed the submit button will read "Resubmit" after you make your first submission to the assignment. To view the paper you have submitted, click the "View" button. Once the assignment's post date has passed, you will also be able to view the feedback left on your paper by clicking the "View" button.

<table>
<thead>
<tr>
<th>Assignment Inbox: TNMGRMU APRIL 2013 EXAMINATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Medical</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Dental</td>
</tr>
</tbody>
</table>
Welcome to your new class homepage! From the class homepage you can see all your assignments for your class, view additional assignment information, submit your work, and access feedback for your papers.
Hover on any item in the class homepage for more information.

This is your class homepage. To submit an assignment click on the "Submit" button to the right of the assignment name. If the Submit button is grayed out, no submissions can be made to the assignment. If resubmissions are allowed the submit button will read "Resubmit" after you make your first submission to the assignment. To view the paper you have submitted, click the "View" button. Once the assignment's post date has passed, you will also be able to view the feedback left on your paper by clicking the "View" button.

<table>
<thead>
<tr>
<th>Assignment</th>
<th>Info</th>
<th>Date Due</th>
<th>Submit</th>
<th>Resubmit</th>
<th>View</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical</td>
<td></td>
<td>Start 21-Nov-2012 11:24AM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Due 31-Dec-2012 11:59PM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Post 07-Jan-2013 12:00AM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dental</td>
<td></td>
<td>Start 27-Nov-2012 12:43PM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Due 31-Dec-2012 11:59PM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Post 07-Jan-2013 12:00AM</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Your digital receipt

This receipt acknowledges that Turnitin received your paper. Below you will find the receipt information regarding your submission.

Paper ID                291381076
Paper title             Multivariate analysis of dengue in a tertiary care hospital
Assignment title        Medical
Author                  Malini 20102243 M.D. Microbiology
E-mail                  malinikesav@yahoo.com
Submission time          17-Dec-2012 09:50PM
Total words              17413

First 100 words of your submission

MULTIVARIATE ANALYSIS OF DENGUE IN A TERTIARY CARE HOSPITAL Dissertation submitted in Partial Fulfillment of the regulations required for the award of M.D DEGREE In Microbiology – Branch IV THE TAMILNADU DR.M.G.R MEDICAL UNIVERSITY, CHENNAI – 600 032 CERTIFICATE This is to certify that the dissertation entitled “MULTIVARIATE ANALYSIS OF DENGUE INFECTION IN A TERTIARY CARE HOSPITAL” is a bonafide work done by Dr.P.Malini, post graduate student in the Department of Microbiology, under the supervision of Dr.K.RAJENDRAN, B.Sc, M.D., Professor & Head Department of Microbiology, Coimbatore Medical College, Coimbatore, in fulfillment of the regulation of the Tamil Nadu Dr.M.G.R Medical University,...
CONTENTS

S.No.                                   Page No.
1. INTRODUCTION                          1
2. AIM AND OBJECTIVES                   4
3. REVIEW OF LITERATURE                 5
4. MATERIALS AND METHODS                34
5. RESULTS                              47
6. DISCUSSION                           64
7. SUMMARY                              78
8. CONCLUSION                           82
9. BIBLIOGRAPHY                         

APPENDICES
   (i) APPENDIX 1
   (ii) APPENDIX 2
   (iii) LIST OF TABLES
   (iv) LIST OF CHARTS
   (v) LIST OF COLOUR PLATES
   (vi) LIST OF ABBREVIATIONS
   (vii) PROFORMA
   (viii) PROTOCOL
   (ix) WORKSHEET
   (x) CONSENT FORM
   (xi) MASTER SHEET
INTRODUCTION

Dengue virus is increasingly recognized as one of the world’s major emerging infectious tropical diseases. According to WHO, Dengue fever or Dengue haemorrhagic fever is considered as the second most important tropical disease next to malaria. Dengue in recent years has become a major international health problem. Annually there are 100 million new dengue viral infections reported worldwide with 5 lakh cases of Dengue haemorrhagic fever (DHF) and Dengue shock syndrome (DSS). There are around 30000 deaths every year which is mostly among children. DHF/DSS is known as one of the leading causes of mortality and morbidity among school going children in Tropical and Subtropical countries.

In India, dengue fever has been known for the past 2 centuries. In India the virus was first isolated in 1945. All the four serotypes are endemic in India. In South India all 4 serotypes of dengue were isolated in Vellore between 1956 & 1960. Later on it started to be reported from other parts of India.

Dengue virus is a single stranded RNA virus with four serotypes. They are DEN1, DEN2, DEN3 & DEN4. Infection with one serotype of Dengue does not confer cross protection against the other serotype. On subsequent infection it may lead to serious forms of disease like Dengue
haemorrhagic fever and Dengue shock syndrome through immuno–pathological enhancement$^{8,7}$.

Clinically Dengue infection causes a wide spectrum of illness ranging from undifferentiated dengue fever, Dengue haemorrhagic fever and Dengue shock syndrome which can finally lead to death$^7$.

Commonly used diagnostic methods for Dengue are viral isolation, RT-PCR and serological methods. Viral isolation is a time consuming and fastidious process that requires specialized laboratory equipments and experienced personnel. RT-PCR even though significantly reduces the processing time and detects the virus in early stage these methods remain expensive and technically difficult particularly in laboratory settings of the developing world$^9$.

Serological diagnosis of Dengue has many advantages like more flexibility, wide availability of reagents, low cost and requirement of less equipments$^7$. One of the definite methods to diagnose early Dengue infection is to detect specific antigen which directly correlate with underlying viremia and pathogenesis of infection$^{10,9}$.

There is no specific treatment or vaccine for Dengue infection. Hence in view of its life threatening complications and increased mortality rate, it is imperative to have rapid and sensitive laboratory methods for early recognition of disease. This helps to identify cases,
initiate treatment at the earliest and to reduce the complications associated with it. Apart from serological parameters, haematological profile and biochemical tests are also helpful as diagnostic markers in the detection of Dengue infection.

In view of the increased occurrence of Dengue and its complications, the study is undertaken to look for seropositivity of Dengue among patients attending tertiary care hospital with categorisation and comparatively evaluate the performance of ELISA and rapid card in the detection of dengue antigen and antibody.
AIM AND OBJECTIVES

Aim: Multivariate analysis of Dengue in a tertiary care hospital.

Objectives of the study:

1. To study the significance of seropositivity of Dengue in a tertiary care hospital.
2. To differentiate serologically between primary and secondary dengue.
3. To detect Dengue NS1 antigen, Dengue IgM and IgG antibody by rapid card method and ELISA technique.
4. To compare and evaluate the efficacy of rapid card with immunocapture ELISA in the diagnosis of dengue infection.
5. To correlate Dengue clinically along with haematological and biochemical markers.
REVIEW OF LITERATURE

History:

- First description of dengue was given by Benjamin Rush in 1780\textsuperscript{11}.
- Mosquito borne transmission of infection by Aedes aegypti was demonstrated in 1903 by Graham, by Bancroft in 1906 and by Cleland et al in 1918\textsuperscript{12}.
- Viral etiology was demonstrated in 1906 by Bancroft.
- Dengue viral serotypes were discovered in 1944\textsuperscript{1}.
- Dengue haemorrhagic fever was described after worldwar –II.
- First epidemic of DHF was reported from patients with haemorrhagic disease during an epidemic in Manila in 1956.
- Sabin and his colleagues showed that virus strains from 3 geographical areas like Hawai, New guinea and India were antigenically similar\textsuperscript{12}.
- The strain isolated from Hawai was called as DENV-1.
- Strain isolated from NewGuinea was called as DENV-2.
- DENV-3 & DENV-4 were isolated later on during epidemics in Manila.
Epidemiology:

The first reported major epidemic was in 1779-80 in Asia, Africa and North America which indicated that these viruses and their mosquito vector had world wide distribution in tropics for more than 200 years\(^7\). Earliest record of Dengue was seen in Chinese encyclopedia of disease symptoms and remedies first published during the JIN dynasty and again in 992 in northern sung dynasty. The disease was called as “water poison” by the Chinese and was thought to be connected with flying insects associated with water\(^{12}\).

Global pandemic of Dengue began in South East Asia . It was first reported from Batavia in Jakarta of Indonesia\(^{12}\) and intensified after world war II. Outbreaks of dengue fever epidemics were documented sporadically with a long gap of 10-30 years. In Southeast Asia, epidemic dengue haemorrhagic fever was first reported in 1950s. In 1975, it became a leading cause of hospitalization and death among children in many countries, with a case fatality rate of 1-5%\(^{13,14}\). After a long interval of 10-40 years second pandemic occurred in Asia in 1980 including China and Taiwan. Dengue viruses were reintroduced in the pacific regions after 25 years in the early 1970s\(^{12}\).
Recent epidemic in Srilanka and India was associated with multiple serotypes but DEN-3 serotype was predominant and different from the previous occurrence. In other countries of Asia where DHF is endemic, the epidemics have become progressively larger in last 15 years.

**Epidemics reported around the world:**

- Chartertower, Australia-1897
- Beirut- 1910
- Taiwan -1916
- Greece- 1928
- Taiwan-1931

Currently dengue fever causes more illness and death than any other Arboviral disease of humans. The incidence has increased over the last 50 years with 2.5 billion people now living in dengue endemic areas. 100 million cases are reported every year worldwide with 5 lakh cases of dengue haemorrhagic fever and dengue shock syndrome. Around 30,000 deaths/year are reported which is mostly among children of 1 to 14 years of age.

**India:** The encounter of Dengue in India is interesting and intriguing. The clinical entity of dengue fever has been known for the past two centuries. Initially it was restricted to east coast of India which later affected most parts of India. It has been endemic in several parts with
interspersed Epidemics. The first major Epidemic in India was reported from Madras in 1780. The dengue virus was first isolated in Calcutta in 1944. Isolation of serotypes 1&4 was in 1964 followed by serotype 3 in 1968. In 1998 Dengue virus subtype 3 of Serotype 3 arose from India and spread to the world\textsuperscript{15}. Since then serotypes were isolated from Vellore, Pondicherry, Chennai, Mangalore, Kolkata, Assam, Lucknow, Delhi & Haryana. Major outbreak of dengue in India was during October 2002 to December 2003. Dengue seems to be an emerging disease in TamilNadu according to Moorthy et al 2009\textsuperscript{16} and in other parts of India where Dengue fever & Dengue haemorrhagic fever have occurred.

Epidemics Reported in India:


Dengue on rise:

Increased incidence and emergence of epidemic DHF is due to

1. Ecological changes

2. Massive human movement during World War II

3. Economic development

4. Unplanned and uncontrolled population growth

5. Uncontrolled urbanization.
6. Air travel by humans.
7. Lack of effective mosquito control in dengue endemic areas\textsuperscript{17,18,12,19}
8. Sub standard housing and inadequate water supply, sewage and waste management systems\textsuperscript{20}.
9. Presence of all four serotypes with secondary infection of a different serotype in the Host\textsuperscript{21,22,17,12}.

**Dengue virus:**

It is an enveloped positive sense ssRNA virus of 35- 40 nm diameter belonging to the Genus Flavivirus and family Flaviviridae. Genus has about 70 distinct viruses. Out of 70, 13 viruses are causing disease in humans and 3 are found to cause increased mortality.

**Genomic structure:**

The genomic RNA is approx. 11 kb in length. It is composed of 3 structural protein genes that encodes nucleocapsid or core protein , a membrane associated (m) protein ,envelope (e) protein and 7 non-structural proteins namely NS1,NS2a,NS2b,NS3,NS4a,NS4b,NS5. NS1 protein is secreted from virus infected cells\textsuperscript{19}. NS1 protein is involved in virion morphogenesis, NS2A and NS3 Protein has virus specific protease. NS3 has helicase activity. The nucleocapsid core is encapsulated by a lipid bilayer membrane. It has 180 copies of membrane proteins and 180
Dengue Virus
copies of envelope proteins which is anchored to it. DENV envelope is found to be the dominant antigen \(^{23}\).

NS1 is 55KDa membrane bound glycoprotein whose function has not been fully determined. NS1 protein is responsible for inducing the soluble complement fixing antigen which is detected in virus infected cells. It is said to contribute to the pathogenesis of Dengue \(^{24,1}\). In children elevated NS1 plasma concentration early in illness are associated with more severe disease reflecting high viral burden \(^7\).

Serotypes of Dengue:

There are 4 serotypes of dengue DEN-1, DEN-2, DEN-3, & DEN-4 depending on antigenic and genetic characterization, \(^{19,16}\). DEN 1 and 3 serotypes share antigenic determinants. Close relation between DEN1 and 4 serotypes has been proved by cDNA hybridization probe. DEN 2 serotype alone shows low sequence homology with all other serotypes.

Dengue epidemic results from introduction of new serotype in areas where already one serotype exists. Asymptomatic to symptomatic infection ratio in dengue viral infection varies with virus strain, age and immune status of the population.

Route of transmission:

Dengue fever is transmitted by the bite of the principal vector mosquitoes called Aedes aegypti followed by other secondary vectors
like Aedes albopictus, Aedes scutellarius & Aedes polynesiensis. In India the common vector is Aedes aegypti. 

Aedes aegypti is an African mosquito. Slave trade between Africa and America and the resulting commerce were responsible for the introduction and widespread geographic distribution of Aedes aegypti in the new world during 17th, 18th, & 19th centuries. It has black and white stripes on the body. Aedes mosquitoes are otherwise called as “Tiger mosquitoes”.

The life span of mosquitoes is increased by moderate temperature and increased humidity. There is a year round transmission between 35°N and 35°S with increased transmission during rainy season. With increasing spread of vector mosquitoes throughout the tropics and subtropics large areas of the world have been vulnerable to the introduction of dengue viruses through air travel by infected humans.

Aedes Mosquitoes has a life span of 1 to 4 weeks. Following infection by dengue virus it requires an extrinsic incubation period of 1 to 2 weeks to become infective to humans. Even though infected it does not suffer from the disease. Sexual transmission occurs from male to female and not vice versa. Females mate only once in their lifetime and can produce eggs at intervals throughout their life. They require blood as the source of protein for maturation of eggs. Digestion of blood meal and
Vector – Female Aedes Aegypti
simultaneous development of eggs takes 2-3 days in the tropics but longer in temperate climates. Female mosquitoes lays 30 -300 eggs at a time.

**Transovarian transmission** in mosquitoes leads to propagation of virus to their progeny and it acts as reservoir for virus maintenance during Inter epidemic periods. Eggs are laid above the water surface and hatch only in water which can happen even in flower vases, water storage jars and rainwater collected in small cups, tyres etc\(^26, 19\). If left dry they remain viable for many weeks.

Adult mosquitoes are indoor daytime biting mosquitoes. Females are said to be nervous feeders. Disruption of the feeding process of mosquitoes takes place even at the slightest movement of the biting person. Aedes will often feed on several persons for a single meal. During this single blood meal, if the mosquito is infective it may transmit dengue virus to multiple persons in a short period of time even if they only probe without taking blood. Because of this behavior it can affect all the family members which makes it an effective **Epidemic vector**\(^{12,19} \). Mosquitoes are normally attracted by body odours, CO\(_2\) and heat emitted from animals/human beings\(^{18} \).

Adult mosquitoes normally shelter indoor and bite at an interval 1-2 hrs particularly during early morning and late afternoon. The
commonest biting area preferred are over the ankles and exposed parts of neck.

Other modes of transmission:

Needle stick injuries\(^1\).

Through blood transfusion in endemic areas during the viremic period\(^{27,28}\).

Vertical transmission of dengue virus to neonates whose mothers had an onset of primary /secondary dengue fever upto 5 weeks before delivery has resulted in acute neonatal dengue manifesting as fever, apnoea, mottling, hepatomegaly and decreased platelet count\(^1\).

Endemic transmission: In endemic countries 1/20 houses may contain infected mosquitoes\(^1\).

Viral replication:

DENGUE DISEASE

“A TICKING TIME BOMB OF HUGE EPIDEMIC POTENTIAL”

Following vector bite ,incoming genomic RNA serves directly as messenger RNA .It has a large open reading frame which is translated completely from its 5’ end to produce a large precursor polyprotein which is again cleaved to produce individual proteins. About ¼\(^{th}\) length of genomic RNA from 5’ end encodes 3 structural proteins and 3’ end encodes for non-structural proteins. Premembrane precursor protein is
cleaved and matures to form ‘M’ (membrane). NS3&NS5 proteins form RNA dependent RNA polymerase complex. NS3 is responsible for co-translational cleavage of nascent polyprotein that yields the NS protein whereas cellular signal peptidases affect other primary cleavage.

Replication occurs in the perinuclear foci leading to synthesis of complementary minus strand which is the template for synthesis of more positive strands during infection. Virion assembly takes place mainly on the endoplasmic reticular membrane in vertebrates and in plasma membrane in invertebrates. Fully formed cell is released usually by cell lysis.

**Pathogenesis and Immunological reaction**

After the bite of an infected mosquito, the virus replicates in local lymph nodes and within 2 to 3 days disseminates through the blood to tissues. Interstitial dendritic cells located in the epithelia are believed to constitute the first line of innate host immune response against invasion of dengue virus. Since phagocytic cells are serving as first line of defense, most of the infections are asymptomatic. Virus circulates in blood for 5
days in infected monocytes and macrophages and to lesser degree in B cells and T cells. It also replicates in the skin, spleen lymphoid cells and macrophages\textsuperscript{1}. Macrophage inflammatory protein-1\(\alpha\) has a pathogenic role in dengue virus infection\textsuperscript{8}.

Infection of monocyte and macrophage is central to the pathogenesis of Dengue fever and origin of Dengue haemorrhagic fever or shock syndrome\textsuperscript{16}. First infection with any of the dengue serotypes results in self limiting febrile illness. Recovery from first infection is usually accompanied by generation of immunological responses. Hence secondary infection with a heterotypic virus will result in severe illness. Epitopes present on Envelope protein are capable of inducing homologous as well as heterologous antibodies.

The plasma leakage is induced by C3a,C5a and several mediators leading to the increased vascular permeability during the acute febrile stage. The plasma leakage is prominent during “critical period” which lasts from 24 hrs before and 24 hours after the day of defervescence of fever\textsuperscript{1}. The evidence of plasma leakage includes hemoconcentration, hypoproteinemia/hypoalbuminemia, pleural effusion, ascites, threatened shock or profound shock\textsuperscript{7}.

Vascular permeability in Dengue Haemorrhagic fever is associated with increased immune activation as manifested by increased levels of
plasma soluble TNF receptor (sTNFR/75) IL-8, IFN-γ, local endothelial proliferation of IL-8, RANTES with apoptotic endothelial cell death. Immune complex formed by antigen and antibody leads to complement activation¹.

The cause of bleeding diathesis in Dengue is complex. It is caused by vasculopathy, thrombocytopenia, platelet dysfunction and coagulopathy². Haemorrhagic diathesis is due to a combination of cytokine activation and vascular injury. Viral antibodies binding to platelets or cross reacting with plasminogen and other clotting factors, decreased platelet function and survival leads to mild consumptive coagulopathy.¹⁰

The pathogenesis of severe disease is not well understood and multiple factors may be implicated. During secondary infection with another serotype, the heterologous antibodies increases the viral uptake not neutralized and replication takes place in Fc receptor bearing cells. This phenomenon is called as Antibody dependent enhancement (ADE)³⁰,³¹,²⁹,¹². This forms the basis of severe dengue infection and in infants with primary infection. ADE- results in high viral load and increased inflammatory response which accounts for capillary leak syndrome⁶. From this it is clear that the dengue vaccine must induce protection simultaneously to all serotypes³².
Dengue haemorrhagic fever is an infrequent but potentially lethal form of illness usually due to secondary infection by heterologous serotype. The pathophysiology of DHF is multifactorial involving viral nature, host genetics, host immunity and previous exposure to the virus. Higher plasma viremia early in the course of infection and consequent T-cell activation predispose to DHF.

In patients with DHF, production of various proinflammatory cytokines/chemokines and complement is increased. Genes encoding for IL-10, IL-8, IL-1β, IL-32/NK4, IFN-γ, TNF-α, MIP-1β, RANTES, CXCL7, CXLI, properdin, and factor D component of complement were more strongly expressed in Peripheral blood mononuclear cells of patients with DHF than DF.

DHF in primary or secondary dengue is due to the occurrence of abnormal immune response involving production of cytokines or activation of T-lymphocytes and disturbance of the hemostatic system. According to Scott B Halstead DHF is not significantly associated with secondary dengue infection as it can result from a virulent dengue virus strain causing primary infection itself.

The mediators like C3a, C5a, TNF-α, interleukin (IL)-2, IL-6, IL-10, IFN-α and histamine are elevated in DHF than Dengue fever.
indicates enhanced activation of cross reactive T cell which leads to increased viral uptake and replication in macrophages and monocytes. This is called as “original antigenic sin”\(^\text{29}\).

Profound T cell activation and death of T cells, during acute dengue infection may suppress or delay viral elimination. This further leads to the higher viral loads and increased immunopathology found in patients with DHF\(^\text{25}\).

Illness after infection with 2 serotypes occurs infrequently and illness after 3 infection virtually never. Repeated episodes of DHF have been recognized rarely, presumably because of immune factors that promote immunopathologic response are outweighed by immune response that clear infection.

**Pathologic feature of Dengue in DHF/DSS-**

Midzonal and hepatocellular necrosis, minimal inflammatory response, councilman bodies, microvesicular fatty changes, hypercellular and hyperplasia of mononuclear phagocytic cells in lymphoid tissue. Atypical lymphocytosis in peripheral blood, widespread infection of mononuclear phagocytes and endothelial cells are seen \(^\text{12}\). The degree of liver dysfunction in dengue infection varies from mild injury with elevation of aminotransferases alone to severe injury with jaundice and hepatic failure. The severity of dengue infection varies depending upon
type of infection and is more in complicated dengue. AST and ALT levels are increased in DHF

Malaise and flu like symptoms in Dengue are due to cytokine response. Myalgia is due to pathological changes in muscle due to moderate perivascular mononuclear infiltrate with lipid accumulation. Severe Musculoskeletal pain indicates viral infection of bone marrow including mobile macrophages and dendritic cells (CD11b/CD18 [Mac-1] positive) and relatively non motile adventitial reticular cells (nerve growth factor receptor positive).

Local suppression of erythrocytes, myelocytic and thrombocytopenic precursors within 4 – 5 days which is reflected in peripheral cytopenia resembling a picture of malignancy. Histopathologic examination of skin show minor degree of lymphocytic dermal vasculitis and variably viral antigen.

Thrombocytopenia and hemoconcentration are constant findings in DHF. A drop in platelet count below 1lakh is seen from 3rd day to 8th day of illness. Hemoconcentration with rise in hematocrit >20% is definitive evidence of plasma leakage. WBC count varies ranging from leucopenia to leucocytosis which is more common towards the end of febrile phase of illness.
Turk cells are transformed lymphocytes. Presence of more than 20% of turk cells in buffy coat smear is a frequent finding of dengue hemorrhagic fever\textsuperscript{34}.

**Immunological Response to Dengue infection:**

The acquired immune response following a dengue infection consists of the production of IgM and IgG antibodies primarily directed against the virus envelope proteins. The immune response differs for primary and secondary infection.

In primary dengue IgM is the first immunoglobulin isotype to appear. IgG is detectable in low titre at the end of first week and slowly increases. In contrast, in secondary dengue antibody titres rise extremely rapidly due to the presence of antibody to the previous infection and these antibodies react broadly with other flaviviruses. High levels of IgG are detectable even in acute phase and rise dramatically over the proceeding 2 weeks. IgM levels are significantly lower in secondary infections. PAHO says that 80% of all dengue cases have IgM antibody by day 5 of illness and 93-99% cases are detectable by 6-10 days and remain detectable upto 90 days. The presence of antibodies in dengue is protective to the infecting serotype but short lived for heterologous serotype. The level of neutralizing antibodies corresponds with protection against dengue virus.
Clinical features:

Incubation period of Dengue is 2 to 7 days and is characterized by high fever, headache, retro orbital pain, lumbosacral pain, conjunctival congestion and facial flushing. Biphasic fever pattern- fever upto 3\textsuperscript{rd} day of onset which subsides and rises again from 5\textsuperscript{th} to 7\textsuperscript{th} day. Because of regular fluctuations in temperature it is also called as ‘\textbf{saddle back}’ fever.

Fever is usually associated with severe generalized myalgia and arthralgia which gives the name as ‘\textbf{Breakbone fever}’. Maculopapular rash appears on the trunk on 1\textsuperscript{st} /2\textsuperscript{nd} day (non irritating rash) then spreads centripetally to the face and limbs but spares palms and soles. Generalised lymphadenopathy, cutaneous hyperaesthesia, altered taste sensation can occur.

Unusual manifestations are neurological, hepatic, renal and isolated organ involvement.

\textbf{According to WHO Guidelines Dengue fever, Dengue haemorrhagic fever and Dengue shock syndrome are defined as follows:}

\textbf{Dengue fever:} fever of 2-7 days associated with symptoms like Arthralgia, myalgia, vomiting, abdominal pain, rash, retro orbital pain, conjunctival congestion, haemorrhagic manifestation, or leucopenia.

\textbf{Dengue haemorrhagic fever: } DHF is defined by the presence of above symptoms plus thrombocytopenia, evidence of increased vascular
permeability (i.e. hemoconcentration, pleural or abdominal effusion, hypoalbuminemia or hypoproteinemia). DHF has 4 grades.

**Dengue shock syndrome**: Defined by the presence of symptoms of DHF with reduced perfusion towards the defervescence and early signs of shock manifested as narrowing of pulse pressure or hypotension for age. The symptoms of DSS are cold clammy extremities, flushed face, diaphoresis, restlessness, irritability and mild epigastric pain\(^{12}\).

Induction of shock in Dengue is influenced by the following:

1. Presence of enhancing and non-reacting antibodies.
2. DHF/DSS is common upto 12 years of age and drops later.
3. Females are affected more than males.
4. Race- Caucasians are affected more.
5. Nutritional status- Malnutrition is said to be protective as they have deficient immune response to infection.
6. Sequence of infection- Serotype 1 followed by Serotype 2 infection is more dangerous.
7. Infecting serotype- Type 2 is apparently more dangerous than other serotypes.

Period of shock is about 1-2 days\(^{18}\) so prompt supportive management and good care with close monitoring during this period would prevent complications and save the life of the patient.
Apart from the above causes, WHO also defines the high risk group as infants and elderly, obesity, Pregnancy, peptic ulcer disease, women who have menstrual / abnormal vaginal bleeding. Other risks factors like G-6PD deficiency, thalessemia and hemoglobinopathies, chronic disease like DM, asthma, SHT are also said to be associated.

**Laboratory Diagnosis:**

Efficient and accurate diagnosis of dengue is of primary importance in detection of cases and early treatment. Laboratory diagnostic methods of detection of dengue are

- Serological methods
- Viral isolation
- Detection of viral nucleic acid.

In **complete blood count** platelet count and the total WBC count would be reduced depending upon the type of fever. As the WBC count becomes low, platelet counts also becomes very low but during the recovery stage WBC count rises rapidly than Platelet count. Platelet count is usually reduced more during the DHF and DSS.

Neutropenia with atypical lymphocytosis resembling malignancy could be seen in peripheral smear. Packed cell volume should be estimated as it rises in Dengue haemorrhagic fever rapidly.
In liver function test – Enzymes like Aspartate aminotransferase and Alanine aminotransferase are elevated depending upon the type of injury.

**Serological methods:**

**Rapid diagnostic tests:**

Various commercial kits are available for dengue detection using the envelope glycoproteins of dengue for IgM and IgG antibody detection and NS1 antibody for antigen detection.

Lateral flow immunochromatographic test allows detection of both antigen and antibody simultaneously with single serum sample, therefore differentiation of primary and secondary dengue can be made with single sample in contrast to multiple samples required for HAI. It produces results within 15-20 minutes and it has the advantage of ease of performance also. But the sensitivity and specificity of these tests are not known and are yet to be evaluated. According to WHO, these RDTs are not be used for clinical management because of false negativity that can lead to missing of diagnosis and fatal complications.

**Enzyme immunosorbent assay (ELISA):**

**Antigen detection:**

Enzyme Immunoassays for antigen detection have four steps. An antigen specific antibody is attached to a solid phase surface. Patient serum that may contain the antigen is added next. An enzyme labeled
antibody specific to the antigen (conjugate) is added. Finally substrate is added which changes colour in the presence of the enzyme. The amount of colour that develops is proportional to the amount of antigen present in the patient specimen.

NS1 protein can be detected by ELISA as soon as first day of fever and can be found up to 9 days in serum even when PCR is negative and where PCR is not available. It might serve as early prognostic marker for severe dengue infections.

**Antibody detection:**

**Immunocapture ELISA:** It is designed to detect a specific type of antibody such as immunoglobulin M or immunoglobulin G. Antibody specific for IgM or IgG is attached to solid phase surface. The patient specimen potentially containing IgM or IgG is added. Specific antigen is added. Finally chromogenic substrate is added which in the presence of the enzyme changes colour. The amount of colour that develops is proportional to the amount of antigen specific IgM or IgG in the patient serum.

Capture ELISA is found to be highly sensitive and is routinely used in diagnosis of dengue infections. They are simple to perform and large number of samples can be tested at the same time.
**A. IgM capture:** It is the widely used ELISA for detection of antibodies. It shows good sensitivity and specificity only when used 5 or more days after onset of fever. A positive result indicates recent infection but cannot identify the serotype. There are different formats of capture ELISA available like capture ultramicro ELISA, dot ELISA, Aubiodot IgM capture ELISA and dipstick. Samples like saliva, serum on filter paper could also be used. Different commercial kits are available with varying sensitivity and specificity.  

**B. IgG capture:** This capture ELISA is commonly used for classifying cases based on type of infection like primary and secondary infection. When used along with IgM the ratio is calculated and according to standard criteria it is classified as primary or secondary. In primary dengue IgG is detected after 2 weeks and persists for life. In secondary dengue IgG antibody to the previous infection rises immediately within 1-2 days before the appearance of IgM. It is followed by IgM to the present infection and IgG after 1 week.

**Other serological methods available for the detection of dengue antibodies:**

**Neutralisation tests:** These tests are technically demanding and time consuming and are performed only in reference laboratories.

**Complement fixation test:** One of the classic methods for demonstrating
the presence of antibody in a patient’s serum has been the complement fixation test. As the procedure is cumbersome, requires highly trained personnel and the reagents are thermolabile it is not used for routine diagnosis\textsuperscript{39}.

**Heamagglutination inhibition test:** This test can be used for suspected DHF/DSS but results are delayed in time when compared to Capture ELISA. Hence it cannot be used for routine diagnostic purposes\textsuperscript{40}.

**Indirect immunofluorescence test**\textsuperscript{41}

**Dot Blot ELISA**\textsuperscript{42}

**Viral isolation:**

**Mosquito Cell lines, mammalian cell lines and adult mosquito inoculation.**

In acute phase of infection isolation and identification of the virus is the only way to diagnose early dengue infection. Serum collected from patient is applied to mosquito cell lines. After amplification of virus in cell line the serotype is identified using monoclonal antibodies. This technique is sensitive only if there is high viremia in the early stages. Common cell lines used are C6/36(Aedes aegypti), AP61(pseudoscutellarius) The CPE on cell lines appears between 1-4 days post inoculation –cells become round and swollen leading to multinucleated giant cells and syncytia formation.
In Mammalian cell culture (LLC-MK2) –CPE occurs after 14 days.

Least sensitive methods are Intra thoracic inoculation of mosquitoes. Eventhough viral culture once considered as ”Goldstandard”, because of its lower sensitivity, long time required and applicable only for acute samples this procedure has been replaced by molecular diagnosis

**Animal inoculation:** Intracerebral inoculation of serum into suckling mice of 1-2 days old done using tuberculin syringe into the lateral hemisphere. After inoculation the mice is observed for sickness daily for any sign of abnormal behavior and if positive it is euthanised, brain tissue is harvested and subjected to relevant tests for confirmation. As this is a tedious procedure and time consuming, it cannot be applied for routine use.

**Detection of Nucleic acid:** RT –PCR provides a rapid and simple method for detection of RNA viruses in serum samples and tissue specimens. Viral genome is amplified using oligonucleotide primers and the amplified product is detected using reverse transcriptase enzyme. Recently conventional RT-PCR has been replaced by Real time PCR which can be automated. Sensitivity ,Specificity and rapid detection of minute quantities of nucleic acid in patient’s serum makes RealTime -PCR more sensitive with less contamination and easy identification of circulating serotype by analyzing the unique sizes of amplicon. Other
methods available for nucleic acid detection are NASBA, Hybridization probes\textsuperscript{44}.

**Differential diagnosis of Dengue fever:** Scrub typhus, Leptospirosis, Malaria, Chikungunya, Influenza, Measles, Rubella\textsuperscript{45}. These diseases could be ruled out by clinical examination and appropriate laboratory tests.

**Dengue vaccine:** More researches have been carried out to develop a dengue vaccine that is safe and immunogenic against all 4 serotypes. Attempts to develop an effective vaccine have been hampered by the lack of understanding of the pathogenesis of disease and absence of suitable experimental model. Dengue vaccine must provide solid and long lasting protection against all dengue virus serotypes. Live attenuated tetravalent candidate vaccine are in the late stage of development which is produced by serial passage of wild type virus in primary dog kidney cells or other cell types\textsuperscript{46}. Sanofi Pasteur has reported successful results of phase II trials of tetravalent recombinant live attenuated vaccine\textsuperscript{47}.

**Non-recombinant candidate vaccine** using structural& non-structural purified proteins and synthetic peptides\textsuperscript{13}

**Recombinant subunit** (Escherichia coli, baculovirus, yeast)\textsuperscript{13}

Recombinant subunit vaccine was produced by coating the $\beta$ domain of dengue serotypes 1-4 to the binding protein of E.coli. Its efficacy was
evaluated in mice as single or tetravalent vaccine. Neutralising antibody titres to each individual serotype was significantly greater than cross reactive neutralising titre compared to tetravalent vaccine. 

**Recombinant vector**

**Infectious cDNA clone technology** has also been exploited for development of dengue vaccine. A chimeric Yellow fever dengue type-2 vaccine prepared by using recombinant cDNA of a Yellow fever vaccine strain as a backbone to which pre membrane and envelope gene of DEN-2 were inserted. It is in Phase II-III trial.

**DNA vaccine** is another novel and promising immunization approach. In order to improve the immunogenicity of DEN-2 candidate vaccine cytoplasmic region of envelope gene was replaced by lysosome associated membrane protein.

**Treatment:** No specific drugs are available for the treatment of Dengue. Proper maintenance of fluid balance is the cornerstone of management in Dengue.

Supportive and symptomatic treatment

- I.V. Fluids, Bed rest
- Paracetamol for control of fever
- Aspirin and NSAIDS must be avoided.
- Platelet and HCT should be monitored daily beginning on the third day of fever.
- Blood and platelet transfusion if required –depending upon the occurrence of bleeding in GI tract but does not correlate with platelet count.
- Early recognition of leakage phase with prompt resuscitation and Close monitoring with oxygen, pulse, blood pressure and urine output would help to reduce complications and improves the treatment outcome.

**Prevention:** Neither vaccine nor specific drugs are available. Hence prevention by vector control of Aedes aegypti plays a major role in Dengue endemic countries.

**Vector control:**
Mosquitoes that rest indoors are easy to control. Female Aedes aegypti are indoor daytime biters. It is difficult to avoid species biting in daytime than those species that bite at night.
Removal or filling of breeding habitats in man made & natural containers, burning of organic waste, screen fitting of mosquito proof lids to drinking water storage containers, installing piped drinking water supply.
Safe and effective larvicides to breeding sites.
Personal protective equipments for the daytime biting mosquitoes are protective clothing like wearing long sleeved clothes, repellents & house screening, indoor space spraying, mosquito coils, mats, bed nets & air conditioning.

Applying insect repellents to both skin and clothing using permethrin is found to be effective. The most effective repellents contain DEET.

**Biological control**

**Antilarval measures:**

1. Eliminating or changing the breeding place to make it unsuitable for development of larvae.
2. Making the breeding place inaccessible to adult mosquitoes.
3. Releasing fish/predators that feed on larvae.
   
   Gambusia affinis /Poecilin reticulate endotoxin producing bacteria (Bacillus thuringiensis serotype H-14, Bacillus sphaeria) and copepod crustaceans are currently used. These are suitable for large containers that are not cleaned regularly as frequent cleaning leads to depletion of nutrients available for the larvae.
4. Applying larvicides wherever necessary.

**Antiadult measures:**

1. Epidemic situations- outdoor space spraying with insecticides.
2. Insecticidal spray are usually applied to parts of town where
Abundant breeding sites are available supporting large population of Aedes.

3. Pyrethrin Knockdown sprays/Organo phosphate sprays can be delivered in microdroplets\textsuperscript{49,26}. 
MATERIALS AND METHODS

Study design: This is a Prospective study

Study period: One Year from September 2011 to August 2012. Approval from Ethical committee obtained for this study.

Inclusion criteria: Patients suffering from fever of 1-12 days duration with any of these symptoms like myalgia, arthralgia, headache, rash, anorexia, nausea, and vomiting, abdominal pain.

Exclusion criteria: Patients suffering from other nonspecific fevers without clinical features suggestive of dengue fever, Urinary tract infections, pneumonia and lung abscess etc.

Statistical analysis: Statistical analysis of results of this study was done using SPSS version 17, p value obtained from chi-square test.

Sample collection: About 5 ml of venous blood was drawn from 350 suspected patients of dengue fever after taking informed consent, under aseptic precautions in sterile containers. These samples were centrifuged at 1500 rpm for 10 minutes & and serum separated. If the sample was not tested immediately it was stored at -20ºc.
Methodology

The serum samples collected were subjected to Dengue duo NS1Ag +Ab combo cassette, NS1 capture ELISA, IgM Capture and IgG Capture ELISA in the Department of Microbiology, at Coimbatore medical college hospital.

Immunochromatography card test (ICT):

Dengue duo combo card:
The rapid test is an in-vitro immunochromatographic one step assay to detect both dengue virus Nonstructural (NS1) antigen and differential IgG/IgM antibodies to dengue virus in serum, plasma or whole blood. The left side of Dengue duocard is the NS1 Ag rapid test for qualitative determination of antigen. It has a circular well for addition of sample. The test device contains a membrane strip precoated with anti-dengue NS1 Ag capture on test band region. The right side of the card is a solid phase immunochromatographic assay for rapid, qualitative and differential detection of IgG and IgM antibodies to dengue virus in serum, plasma and whole blood. The card has a square well for sample addition, a circular well for buffer and a lateral flow
membrane with colloidal gold conjugate containing recombinant dengue antigen and a control.

**Principle of the test:**

The dengue NS1 antigen card can identify dengue virus NS1 antigen in serum, plasma or whole blood specimens with a high degree of sensitivity and specificity. Dengue IgG/IgM rapid test is designed to simultaneously detect and differentiate IgG, IgM antibodies to dengue virus. This test can also detect all 4 serotypes by using a mixture of recombinant dengue envelope proteins.

When a specimen is added to the sample well anti-dengue IgG & IgM antibodies in the specimen will react with recombinant dengue envelope proteins – colloidal gold conjugates and forms a complex of antibody-antigen. As this complex migrates along the length of test device by capillary action, it will be captured by the relevant anti-human IgG and/or anti-human IgM immobilized in 2 test lines across the test device and generate a coloured line.

**Procedure:**

1. The card was placed on an even surface after being unwrapped from the cover. Id no & date noted down on the card
2. With the dropper provided 10 µl of serum was added to the sample well followed by 4 drops of buffer on the right side of the card.

3. With another dropper provided 100µl of sample was added to the antigen well on the left side of the card.

4. Results were read after 15-20 minutes.

**Results:**

**Antibody**

1. Appearance of bands in all the lines on the antibody card

2. Appearance of control & “M” line alone

3. Appearance of control &”G” line alone.

4. Appearance of control line alone

**Antigen:**

Appearance of bands in control area alone

Appearance of bands in control and test regions.

**Interpretation:**

1. **Antibody :**
   
a. Presence of control line alone- test is negative for antibodies.

b. Presence of all the lines control, M and G – both IgM &IgG Positive -Indicates either late primary or early secondary infection

c. Presence of control and M line alone- primary dengue

d. Presence of control and G line alone- secondary or past dengue
e. Absences of control line – invalid and test to be repeated.

2. Antigen:
   
a. Presence of bands in both test & control area – positive for NS1 antigen.

b. Presence of band in control area alone – negative for antigen

c. No bands in the result window, it is invalid – test has to be repeated.

**Dengue EARLY ELISA**

**Principle of the test:** NS1 antigen present in the serum binds to the anti-NS1 coated on the microwell strips. The unbound antigen if present is removed by the washing step. HRP conjugated monoclonal anti-NS1 antibody is added. A colourless substrate TMB is added which produces blue colour. On addition of stop solution phosphoric acid it changes to yellow colour.

**Procedure:**

1. 100µl of diluted sample & controls were added into the respective wells

2. The plate was covered & incubated for 1 hour at 37°C

3. At the end of 1 hour Plate was washed 6 times with diluted wash buffer
4. 100µl of Horseradish peroxidase (HRP) conjugate was added into the well.

5. The plate was Covered & incubated at 37°C for 1 hour.

6. Washed 6 times with diluted wash buffer at the end of incubation.

7. 100µl of Tetramethylbenzidine (TMB) was added into each well

8. Incubated for 10 mts at Roomtemperature (RT) & observed for blue colour

9. 100µl of stop solution was added & the change of colour noted.

10. Absorbance value of each well measured at 450 nm with reference filter 600-650nm spectrophotometrically.

**Calculation:**

Average absorbance of calibrator triplicate multiplied by the calibration factor

Cut off value (COV) = absorbance of calibrator X cal. Factor

Cal.factor=0.57

Index value= sample OD/ cutoff value

Panbio units= Index value x 10
Test validity:

Negative absorbance < 0.250

COV >1.5 X Negative absorbance.

Positive control/ cutoff ratio= 1.1-7.0

Interpretation:

<table>
<thead>
<tr>
<th>Index</th>
<th>Panbiounits</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0.9</td>
<td>&lt; 9</td>
<td>Negative</td>
</tr>
<tr>
<td>0.9-1.1</td>
<td>9-11</td>
<td>Equivocal</td>
</tr>
<tr>
<td>&gt;1.1</td>
<td>&gt; 11</td>
<td>Positive</td>
</tr>
</tbody>
</table>

Dengue IgM capture ELISA:

Principle of the test:

Serum antibodies of the IgM class, when present, combine with anti-human IgM antibodies coated on the polystyrene surface of the microwell test strips (assay plate). The diluted recombinant antigen is mixed with equal volume of horseradish peroxidase (HRP) conjugated monoclonal antibody (MAb) allowing the formation of antigen-MAb complexes. Addition of complexed antigen-MAb complexes following washing will bind to the serum dengue-specific IgM antibodies. After incubation a colourless substrate tetramethylbenzidine/hydrogen peroxide
(TMB Chromogen) is added. The substrate is hydrolysed by HRP if present, and the chromogen turns blue. After stopping the reaction with acid, the TMB turns yellow. Colour development is indicative of the presence of anti-dengue IgG antibodies in the test sample.

**Procedure:**

All the kit reagents were brought to room temperature before start of the test.

**ELISA Procedure:**

1. Dispensed 100µl of diluted patient serum, positive and negative control, calibrator in triplicate added to their respective wells in the microtiter plate.

2. The microtiter plate was covered and incubated at 37\(^0\) C for 1 hour

3. Antigen was diluted in 1/250 with antigen diluent i.e 10µl of antigen in 2.5ml of antigen diluent.

4. Required amount of diluted antigen is mixed with equal volume of Monoclonal antibody tracer and incubated at room temperature until required.

5. The plate was washed 6 times with diluted wash buffer at the end of incubation.
6. Added 100µl of antigen antibody mixture to all the wells

7. The plate was covered and incubated at 37°C for 1 hour.

8. At the end of incubation, plate was washed 6 times with diluted wash buffer

9. Added 100µl of TMB substrate to the wells and incubated in the dark for 10 minutes.

10. 100µl of stop solution added to all the wells.

11. Absorbance value of each well measured spectrophotometrically at 450nm wavelength with reference filter of 600-650nm.

**Calculation:**

- Average absorbance of the triplicate of the calibrator multiplied by the calibration factor. This is the cutoff-value.

- An index value is calculated by dividing the sample absorbance by the cut-off value

  Index value = sample absorbance/ cut-off value

  Panbio units= Indexvalue x 10
**Test validity:**

Cutoff value > 1.5x neg. absorbance

Calibrator mean > negative absorbance

Positive control/cutoff value = 1.1-8

Negative control < 0.40

Calibration factor = 0.99

**Interpretation of results:**

<table>
<thead>
<tr>
<th>INDEX</th>
<th>PANBIOUNITS</th>
<th>RESULT</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.9</td>
<td>&lt; 9</td>
<td>Negative</td>
</tr>
<tr>
<td>0.9-1.1</td>
<td>9-11</td>
<td>Equivocal</td>
</tr>
<tr>
<td>&gt;1.1</td>
<td>&gt;11</td>
<td>Positive</td>
</tr>
</tbody>
</table>

**Dengue IgG capture ELISA**

**Principle of the test:** Serum antibodies of the IgG class, when present, combine with anti-human IgG antibodies coated on the polystyrene surface of the microwell test strips (assay plate). An equal volume of horseradish peroxidase (HRP) conjugated monoclonal antibody (MAb) is added to the diluted antigen, allowing the formation of antigen-MAb complexes. Residual serum is removed from the assay plate by washing, and complexed antigen-MAb complexes added then bind to the serum dengue-specific IgG antibodies. After incubation a colourless substrate
added to the washed wells and was followed by tetramethylbenzidine/hydrogen peroxide (TMB Chromogen) addition. The substrate is hydrolysed by HRP if present, and the chromogen turns blue. After stopping the reaction with acid, the TMB turns yellow, Colour development is indicative of the presence of anti-dengue IgG antibodies in the test sample.

Preprocedure preparation:
All the kit reagents were brought to room temperature before the commencement of the procedure.

Procedure:
Antigen diluted 1/250 using antigen diluent i.e. 10µl antigen mixed with 2.5ml of antigen diluent. About 0.5ml of diluted antigen is required per strip.

Equal volume of diluted antigen mixed with monoclonal antibody tracer solution. This is incubated at room temperature for 1 hour.

1. Dispensed 100 µl of diluted sample, positive control, negative control and calibrators in triplicate to the respective wells

2. The plate was covered and Incubated at 37 °C for 1 hour.

3. Plate was washed 6 times with diluted wash buffer at the end of incubation
4. Added 100 µl of Ag–MAb tracer solution to all the wells at the end of incubation

5. Plate was covered and Incubated at 37°C for 1 hour.

6. Washed 6 times with wash buffer at the end of incubation.

7. Added 100 µl of TMB was to all the wells.

8. Incubated at dark for 10 minutes.

9. Added 100µl of stop solution to all the wells

10. Absorbance value of each well measured at 450 nm wavelength with 600-650 nm reference filter spectrophotometrically.

**Calculation:**

1. The average absorbance of the triplicate of the calibrator is multiplied by the calibration factor. This is the cut-off value.

2. Index value is calculated by dividing the sample absorbance by the cut-off value.

**Test validity:**

Cutoff value= 1.5x neg.absorbance

Calibrator mean >negative absorbance

Positive control/Cutoff value= 1.1-6.0
Negative control<.350

Calibration factor=1

Index value= Sample absorbance / cutoff value

Panbio units= index value x 10

**Interpretation of results:**

<table>
<thead>
<tr>
<th>INDEX</th>
<th>PANBIOUNITS</th>
<th>RESULT</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1.8</td>
<td>&lt;18</td>
<td>Negative</td>
</tr>
<tr>
<td>1.8-2.2</td>
<td>18-22</td>
<td>Equivocal</td>
</tr>
<tr>
<td>&gt;2.2</td>
<td>&gt;22</td>
<td>Positive</td>
</tr>
</tbody>
</table>

The haematological and biochemical profile of dengue positives were estimated in the respective Departments and results were collected.
Dengue Duo Combo Card Kit

NS1 Positive
NS1 with IgM Positive

NS1 with IgM and IgG Positive

NS1 with IgG
NS1 Negative with IgM and IgG Positive

IgM antibody positive

IgG Antibody Positive
IgG ELISA Kit

ELISA Reader
Antigen Antibody Mixture of IgM & IgG

MicrotitrePlate with Samples
Microtitre Plate with Samples after substrate Addition

Samples after addition of Stop Solution
RESULTS

During the study period of one year Blood was collected from 350 clinically suspected dengue cases. The samples were subjected to Dengue serology for both NS1 antigen and IgM, IgG antibody detection by ELISA and ICT. The 107 seropositive samples by ELISA were further analysed for demographic, clinical and laboratory data including haematological and biochemical profile. The Statistical analysis of results of this study was done using SPSS version 17. P value obtained from pearson chi-square test.

In this study the seropositivity of dengue was 30% (Ref Table 1).

The age of the seropositives ranged from 0-72 years and the commonest age group affected in this study was 0-10 years 45 (42%) followed by 11-20 years 27 (25.2%), 21-30 years 16 (14.9%), 31-40 years 12 (11.2%). The incidence was less in the age group of 41-50 years and 51-60 years each constituting about 2 (1.8%) and >60 years 3 (2.8%). (Ref Table 2)

The male: female ratio was 1.6:1 in this study with males 67 (62.3%) and females 40 (37.7%) (Ref Table 2).

The incidence of dengue cases in this study month wise were September 2 (16.6%), October 0 (0%) November 5 (21.7%), December 12
(25.5%), January 13 (31.7%), February 2 (13.3%), March 1 (4.3%), April 4 (23.5%), May 13 (26.5%), June 41 (50.6%) and July 13 (52%) and August 1 (12.5%). (Ref Table 3).

The common clinical symptom was fever 107 (100%), followed by headache 65 (60.7%), Myalgia 41 (38.3%), Arthralgia 32 (29.9%), Abdominal pain 30 (28.03%), vomiting 26 (24.2%), Oliguria and Rash was observed in 5 cases(4.6%). (Ref Table 4)

Melena 11 (10.2%) was the commonest bleeding manifestation followed by bleeding gums 5 (4.6%), Hemetemesis 4 (3.7%) and Epistaxis 3 (2.8%) (Ref Table 4)

The positive cases were classified as Dengue fever 52 (48.5%), Dengue haemorrhagic fever 53 (49.5%) and Dengue shock syndrome 2 (2%) according to WHO guidelines. (Ref Table 5).

In this study thrombocytopenia was associated with majority of Dengue positive cases. The common range was 51,000-1lakh 44 (41.1%) followed by 21000-40,000 30 (28.03%), <20,000 13 (12.14%), 41,000-50,000 10 (9.34%) and >1lakh 10 (9.34%). Among thrombocytopenia <1lakh 43 (82.6%)
were associated with dengue fever, 52 (98%) with Dengue haemorrhagic fever and 2 (100%) with Dengue shock syndrome. (Ref Table 6 & 9).

In this study leucopenia (count <4000) was observed in 79 (73.8%) dengue positive cases. Out of 52 Dengue fever cases 37 had leucopenia (71.1%), out of 53 DHF 40 had leucopenia (75.4%) and out of 2 DSS both had leucopenia (100%). Eight cases (7.5%) had WBC count of 4000-5000, 7 were in 5100-6000 (6.5%) range, 6 were in 6100-7000 range and 7 cases had count >7000 (6.5%). (Ref Table 7 & 9).

Elevated Haematocrit > 45% was observed in 33 (30.8%) cases. Among them 5 (9.6%) were associated with Dengue fever and 26 (49.05%) with Dengue haemorrhagic fever and 2 (100%) with Dengue shock syndrome. HCT level in other cases were 35-44 in 30 (28.03%) cases, 25-34 in 34 (31.7%) and <25 in 10 case (9.3%). (Ref Table 8 & 9)

Liver parameters like ALT and AST were raised in 24 (22.4%) and 28 (26.1%) cases respectively. Among ALT elevated cases 8 (15.3%) were associated with Dengue fever, 14 (26.4%) were associated with Dengue haemorrhagic fever and 2 (100%) were associated with Dengue shock syndrome. Among AST elevated cases 10 (19.2%) were associated with
Dengue fever, 16 (30.1%) were associated with Dengue haemorrhagic fever and 2 (100%) were associated with Dengue shock syndrome. (Ref Table 10)

In Ultrasonogram (USG) Gallbladder thickening 31 (28.9%) was observed in majority of Dengue positive cases followed by pleural effusion 16 (14.9%), ascites 9 (8.4%) and hepatomegaly 7 (6.5%). Among GB thickening 5 (9.6%) were associated with Dengue fever, 24 (45.2%) with Dengue haemorrhagic fever, 2 (100%) with Dengue shock syndrome. Pleural effusion of 14 (26.4%) were associated with Dengue haemorrhagic fever and 2 (100%) were associated with Dengue shock syndrome and nil case in Dengue fever. Ascites of 7 (13.2%) were associated with Dengue haemorrhagic fever, 2 (100%) with Dengue shock syndrome and nil case in Dengue fever. Hepatomegaly was associated with dengue fever 5 (9.6%) and Dengue haemorrhagic fever 2 (3.7%) and nil association with Dengue shock syndrome. USG was normal in 30 (28.03%) cases which was 25 (48%) in Dengue fever and 5 (9.4%) in Dengue haemorrhagic fever. USG was not available for 17 cases of Dengue fever and 1 case in Dengue haemorrhagic fever. (Ref Table 11)

Seropositives were categorised as Primary 48 (44.9%) and secondary dengue 59 (55.1%) with ratio 0.8:1 based on ELISA. The serological markers
included for primary dengue were NS1 alone positive, NS1 with IgM positive, IgM alone positive and IgM & IgG positive with ratio >1. The serological markers and their combination included for secondary dengue were IgG positive with thrombocytopenia, NS1 & IgG positive, NS1, IgM & IgG positive and IgM & IgG positive with ratio <1. (Ref Table 12)

Based on duration of fever, primary dengue cases with above mentioned markers were split into 1-5 days (37), 6-10 days (10) and >10 days (1).

In primary Dengue (PD) NS1 alone showed positivity of 27 (56.25%), NS1 & IgM showed positivity of 8 (16.6%), IgM alone showed positivity of 9 (18.75%), IgM & IgG +ve with ratio >1 showed positivity of 4 (8.33%).

In 1-5 days period NS1 alone showed positivity of 27 (72.9%) followed by NS1 & IgM positivity of 8 (21.6%) and IgM, alone positive of 2 (5.4%). In 6-10 days duration IgM alone showed positivity of 70% followed by IgM & IgG positive with ratio >1 positivity of 3 (30%). NS1 and NS1 with IgM showed nil positivity. In >10 days IgM & IgG positive with ratio >1 alone had positivity of 100%, others were nil during this period. With
p value<0.001 it was found to be statistically significant. (Ref Table 13)

Similarly in secondary dengue (SD) IgG positive with thrombocytopenia showed positivity of 6(10.1%), NS1 & IgG of 1(1.6%), NS1,IgM & IgG of 14(23.7%), IgM & IgG positive with ratio <1 of 38(64.4%).

In 1-5 days of secondary dengue NS1,IgM & IgG 11(47.8%) showed higher positivity followed by IgM & IgG positive with ratio <1 6(26.08%), IgG positive with thrombocytopenia were 5(21.7%), NS1 & IgG positive 1(4.3%).

In 6-10 days IgM & IgG positive with ratio <1 showed positivity of 22(84.6%) followed by NS1, IgM, IgG positivity of 3(11.5%) and IgG positive with thrombocytopenia 1(3.8%). In >10 days duration IgM & IgG positive with ratio <1 showed higher positivity of 10(100%). Others showed nil positivity. With p value<0.001 it was found to be statistically significant. (Ref Table 14)

Case detection by ICT and ELISA showed 26.2% positivity for ICT and 30.5% positivity for ELISA. (Ref Table 15)
Detection of serological markers like NS1, IgM and IgG by ICT and ELISA showed positivity of 36(10.2%), 62(17.7%), 54(15.4%) by ICT and 50(14.2%), 73(20.8%), 65(18.2%) respectively by ELISA (Ref Table 15a).

Using ELISA as Reference assay, Sensitivity, Specificity, NPV and PPV of the ICT were calculated for NS1 which showed 68%, 99.3%, 94.4%, and 85.7% respectively. With p value of <0.001 it was found to be statistically significant. (Ref Table 16)

Similarly for IgM the ICT showed sensitivity, specificity, PPV, NPV of 80.8%, 98.9%, 95.1%, and 95.1% respectively. With p value<0.05 it was found to be statistically significant. (Ref Table 17).

Sensitivity, Specificity, PPV, and NPV of IgG in ICT was 81.3%, 98.9%, 94.1%, 96.32% respectively. With p value<0.001 it was found to be statistically significant. (Ref Table 18)
### Table 1

**Seropositivity of Dengue**

<table>
<thead>
<tr>
<th>Total No. of Suspected fever Cases</th>
<th>Total No. of positive cases</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>350</td>
<td>107</td>
<td>30.5%</td>
</tr>
</tbody>
</table>

### Table 2

**Age and Sex Wise Distribution of Dengue positive cases**

<table>
<thead>
<tr>
<th>S.No.</th>
<th>Age Group</th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>0-10 Yrs</td>
<td>26(24.2%)</td>
<td>19(17.7%)</td>
<td>45(42%)</td>
</tr>
<tr>
<td>2.</td>
<td>11-20 Yrs</td>
<td>18(16.8%)</td>
<td>09(8.4%)</td>
<td>27(25.2%)</td>
</tr>
<tr>
<td>3.</td>
<td>21-30 Yrs</td>
<td>10(9.3%)</td>
<td>06(5.6%)</td>
<td>16(14.9%)</td>
</tr>
<tr>
<td>4.</td>
<td>31-40 Yrs</td>
<td>10(9.3%)</td>
<td>02(2.0%)</td>
<td>12(11.2%)</td>
</tr>
<tr>
<td>5.</td>
<td>41-50 Yrs</td>
<td>01(0.9%)</td>
<td>01(1%)</td>
<td>02(1.8%)</td>
</tr>
<tr>
<td>6.</td>
<td>51-60 Yrs</td>
<td>-</td>
<td>02(2.0%)</td>
<td>02(1.8%)</td>
</tr>
<tr>
<td>7.</td>
<td>&gt;60 Yrs</td>
<td>02(1.8%)</td>
<td>01(1.0%)</td>
<td>03(2.8%)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td><strong>67(62.3%)</strong></td>
<td><strong>40(37.7%)</strong></td>
<td><strong>107(100%)</strong></td>
</tr>
</tbody>
</table>

**Male: Female ratio 1.6:1**
### Table 3
Seasonal Distribution of Dengue positive Cases

<table>
<thead>
<tr>
<th>Month</th>
<th>Total no of cases</th>
<th>No of Positives</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011-2012</td>
<td>350</td>
<td>107</td>
<td></td>
</tr>
<tr>
<td>September</td>
<td>12</td>
<td>2</td>
<td>16.6</td>
</tr>
<tr>
<td>October</td>
<td>9</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>November</td>
<td>23</td>
<td>5</td>
<td>21.7</td>
</tr>
<tr>
<td>December</td>
<td>47</td>
<td>12</td>
<td>25.5</td>
</tr>
<tr>
<td>January</td>
<td>41</td>
<td>13</td>
<td>31.7</td>
</tr>
<tr>
<td>February</td>
<td>15</td>
<td>2</td>
<td>13.3</td>
</tr>
<tr>
<td>March</td>
<td>23</td>
<td>1</td>
<td>4.3</td>
</tr>
<tr>
<td>April</td>
<td>17</td>
<td>4</td>
<td>23.5</td>
</tr>
<tr>
<td>May</td>
<td>49</td>
<td>13</td>
<td>26.5</td>
</tr>
<tr>
<td>June</td>
<td>81</td>
<td>41</td>
<td>50.6</td>
</tr>
<tr>
<td>July</td>
<td>25</td>
<td>13</td>
<td>52</td>
</tr>
<tr>
<td>August</td>
<td>8</td>
<td>1</td>
<td>12.5</td>
</tr>
</tbody>
</table>

\[ \text{chi square test} = 30.7, \ p \text{ value} < .001 \text{(significant)} \]
Table 4

Clinical Presentation of Dengue positive cases

<table>
<thead>
<tr>
<th>Symptom</th>
<th>No. of Patients</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>107</td>
<td>100%</td>
</tr>
<tr>
<td>Headache</td>
<td>65</td>
<td>60.7%</td>
</tr>
<tr>
<td>Myalgia</td>
<td>41</td>
<td>38.3%</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>32</td>
<td>29.9%</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>30</td>
<td>28.03%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>26</td>
<td>24.2%</td>
</tr>
<tr>
<td>Melena</td>
<td>11</td>
<td>10.2%</td>
</tr>
<tr>
<td>Oliguria</td>
<td>5</td>
<td>4.6%</td>
</tr>
<tr>
<td>Bleeding gums</td>
<td>5</td>
<td>4.6%</td>
</tr>
<tr>
<td>Rash</td>
<td>5</td>
<td>4.6%</td>
</tr>
<tr>
<td>Hematomesis</td>
<td>4</td>
<td>3.7%</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>3</td>
<td>2.8%</td>
</tr>
</tbody>
</table>

Table 5

Clinical Classification based on WHO Guidelines

<table>
<thead>
<tr>
<th>Category</th>
<th>No. of Positive Cases</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dengue Fever</td>
<td>52</td>
<td>48.5%</td>
</tr>
<tr>
<td>Dengue Hemorrhagic Fever</td>
<td>53</td>
<td>49.5%</td>
</tr>
<tr>
<td>Dengue Shock Syndrome</td>
<td>2</td>
<td>2%</td>
</tr>
<tr>
<td>Total</td>
<td>107</td>
<td>100%</td>
</tr>
</tbody>
</table>

chi-square test =47.68, p<0.001(significant)
### Table 6
Platelet Count in Dengue positive cases (n = 107)

<table>
<thead>
<tr>
<th>Platelet Count</th>
<th>Total cases</th>
<th>Percentage %</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;20,000</td>
<td>13</td>
<td>12.14</td>
</tr>
<tr>
<td>21,000 – 40,000</td>
<td>30</td>
<td>28.03</td>
</tr>
<tr>
<td>41,000 – 50,000</td>
<td>10</td>
<td>9.34</td>
</tr>
<tr>
<td><strong>51,000 – 1 lakh</strong></td>
<td><strong>44</strong></td>
<td><strong>41.12</strong></td>
</tr>
<tr>
<td>&gt;1 Lakhs</td>
<td>10</td>
<td>9.34</td>
</tr>
<tr>
<td>Total</td>
<td>107</td>
<td>100</td>
</tr>
</tbody>
</table>

chi-square test=42.766, pvalue<0.001 (significant)

### Table 7
WBC Count of Dengue positive cases (n = 107)

<table>
<thead>
<tr>
<th>WBC Count</th>
<th>Total cases</th>
<th>Percentage %</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 4000</td>
<td>79</td>
<td>73.8</td>
</tr>
<tr>
<td>4000 – 5000</td>
<td>8</td>
<td>7.5</td>
</tr>
<tr>
<td>5100 – 6000</td>
<td>7</td>
<td>6.5</td>
</tr>
<tr>
<td>6100 – 7000</td>
<td>6</td>
<td>5.6</td>
</tr>
<tr>
<td>&gt;7000</td>
<td>7</td>
<td>6.5</td>
</tr>
<tr>
<td>Total</td>
<td>107</td>
<td>100</td>
</tr>
</tbody>
</table>

chi-square test=42.7, p value<0.001 (significant)
Table 8

Level of HCT in Dengue positive cases (n = 107)

<table>
<thead>
<tr>
<th>HCT</th>
<th>Total cases</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;45</td>
<td>33</td>
<td>30.8</td>
</tr>
<tr>
<td>35-44</td>
<td>30</td>
<td>28.03</td>
</tr>
<tr>
<td>25-34</td>
<td>34</td>
<td>31.7</td>
</tr>
<tr>
<td>&lt;25</td>
<td>10</td>
<td>9.3</td>
</tr>
<tr>
<td>Total</td>
<td>107</td>
<td>100</td>
</tr>
</tbody>
</table>

chi square test= 42.7, p value <0.001 (significant)

Table 9

Association of platelet, Haematocrit and WBC with Dengue positives

<table>
<thead>
<tr>
<th>Category</th>
<th>Platelet count &lt; 1 lakh(97)</th>
<th>Haematocrit &gt;45(33)</th>
<th>WBC count &lt;4000(79)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dengue fever(52)</td>
<td>43(82.6%)</td>
<td>5(9.6%)</td>
<td>37(71.1%)</td>
</tr>
<tr>
<td>Dengue hemorrhagic fever(53)</td>
<td>52(98.1%)</td>
<td>26(49.05%)</td>
<td>40(75.4%)</td>
</tr>
<tr>
<td>Dengue shock syndrome(2)</td>
<td>2(100%)</td>
<td>2(100%)</td>
<td>2(100%)</td>
</tr>
<tr>
<td>Total</td>
<td>97</td>
<td>33</td>
<td>79</td>
</tr>
</tbody>
</table>
Table 10

Association of ALT and AST in Dengue positive cases

<table>
<thead>
<tr>
<th>Category</th>
<th>ALT&gt;40(24)</th>
<th>AST&gt;40(28)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dengue fever (52)</td>
<td>8(15.3%)</td>
<td>10(19.2%)</td>
</tr>
<tr>
<td>Dengue haemorrhagic fever (53)</td>
<td>14(26.4%)</td>
<td>16(30.1%)</td>
</tr>
<tr>
<td>Dengue shock syndrome (2)</td>
<td>2(100%)</td>
<td>2(100%)</td>
</tr>
<tr>
<td>Total</td>
<td>24(22.4%)</td>
<td>28(26.1%)</td>
</tr>
</tbody>
</table>

chi-square test=12.1, pvalue <0.05(significant)

Table 11

USG Findings in Dengue positive cases

<table>
<thead>
<tr>
<th>Category</th>
<th>Normal %</th>
<th>GB thickening %</th>
<th>Pleural effusion %</th>
<th>Ascites %</th>
<th>Hepatomegaly %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dengue fever (52)</td>
<td>25(48)</td>
<td>5(9.6)</td>
<td>0</td>
<td>0</td>
<td>5(9.6)</td>
</tr>
<tr>
<td>Dengue haemorrhagic fever (53)</td>
<td>5(9.4)</td>
<td>24(45.2)</td>
<td>14(26.4)</td>
<td>7(13.2)</td>
<td>2(3.7)</td>
</tr>
<tr>
<td>Dengue shock syndrome (2)</td>
<td>0</td>
<td>2(100)</td>
<td>2(100)</td>
<td>2(100)</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>30(28.03)</td>
<td>31(28.9)</td>
<td>16(14.9)</td>
<td>9(8.4)</td>
<td>7(6.5)</td>
</tr>
</tbody>
</table>
Table 12
Serological Categorisation of Dengue positives based on ELISA

<table>
<thead>
<tr>
<th>Category</th>
<th>No. of Positive Cases</th>
<th>Percentage</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Dengue</td>
<td>48</td>
<td>44.9%</td>
<td>0.8:1</td>
</tr>
<tr>
<td>Secondary Dengue</td>
<td>59</td>
<td>55.1%</td>
<td></td>
</tr>
</tbody>
</table>

Table 13
Primary dengue based on duration of fever & serological markers

<table>
<thead>
<tr>
<th>Fever duration</th>
<th>NS1 positive</th>
<th>NS1&amp;IgM Positive</th>
<th>IgM alone Positive</th>
<th>IgM &amp; IgG+ve with Ratio &gt;1</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-5 Days</td>
<td>27 (72.9%)</td>
<td>8 (21.6%)</td>
<td>2 (5.4%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>(37)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6–10 Days</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>7 (70%)</td>
<td>3 (30%)</td>
</tr>
<tr>
<td>(10)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 10 days</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>1 (100%)</td>
</tr>
<tr>
<td>(1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>27 (56.25%)</td>
<td>8 (16.6%)</td>
<td>9 (18.75%)</td>
<td>4 (8.33%)</td>
</tr>
<tr>
<td>(48)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

chi-square test=47.07, p value<0.001 (significant)
Table 14

Secondary Dengue based on duration of fever and serological markers

<table>
<thead>
<tr>
<th>Fever duration</th>
<th>IgG+thrombocytopenia</th>
<th>NS1 &amp; IgG Positive</th>
<th>NS1, IgM &amp; IgG Positive</th>
<th>IgM&amp;IgG+ve with Ratio &lt;1</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-5 Days (23)</td>
<td>5 (21.7%)</td>
<td>1 (4.3%)</td>
<td>11 (47.8%)</td>
<td>6 (26.08%)</td>
</tr>
<tr>
<td>6 – 10 Days (26)</td>
<td>1 (3.8%)</td>
<td>0 (0.0%)</td>
<td>3 (11.5%)</td>
<td>22 (84.6%)</td>
</tr>
<tr>
<td>&gt; 10 Days (10)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>10 (100%)</td>
</tr>
<tr>
<td>Total (59)</td>
<td>6 (10.1%)</td>
<td>1 (1.6%)</td>
<td>14 (23.7%)</td>
<td>38 (64.4%)</td>
</tr>
</tbody>
</table>

chi-square test= 25.12, P value<0.001 (significant)

Table 15

Case detection by ICT and ELISA

<table>
<thead>
<tr>
<th>Test</th>
<th>No. of Suspected Cases</th>
<th>No. of Positive Cases</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICT</td>
<td>350</td>
<td>92</td>
<td>26.2%</td>
</tr>
<tr>
<td>ELISA</td>
<td>350</td>
<td>107</td>
<td>30.5%</td>
</tr>
</tbody>
</table>
Table 15(a)
Detection of NS1, IgM, IgG by ICT and ELISA

<table>
<thead>
<tr>
<th>Test</th>
<th>No of suspected cases</th>
<th>ICT</th>
<th>ELISA</th>
</tr>
</thead>
<tbody>
<tr>
<td>NS1</td>
<td>350</td>
<td>36(10.2%)</td>
<td>50(14.2%)</td>
</tr>
<tr>
<td>IgM</td>
<td>350</td>
<td>62(17.7%)</td>
<td>73(20.8%)</td>
</tr>
<tr>
<td>IgG</td>
<td>350</td>
<td>54(15.4%)</td>
<td>65(18.2%)</td>
</tr>
</tbody>
</table>

Table 16
Cross tabulation of ICT and ELISA for NS1

<table>
<thead>
<tr>
<th>ICT</th>
<th>ELISA</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>Positive</td>
<td>34</td>
<td>2</td>
</tr>
<tr>
<td>Negative</td>
<td>16</td>
<td>298</td>
</tr>
<tr>
<td>Total</td>
<td>50</td>
<td>300</td>
</tr>
</tbody>
</table>

Sensitivity 68%, Specificity 99.3%, PPV 94.4%, NPV 85.7%  
chi-square test =46.36, p value<0.001(significant)
Table 17

Cross tabulation of ICT and ELISA for IgM

<table>
<thead>
<tr>
<th>ICT</th>
<th>ELISA</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>Positive</td>
<td>59</td>
<td>3</td>
</tr>
<tr>
<td>Negative</td>
<td>14</td>
<td>274</td>
</tr>
<tr>
<td>Total</td>
<td>73</td>
<td>277</td>
</tr>
</tbody>
</table>

Sensitivity 80.8%, Specificity 98.9%, PPV 95.1%, NPV 95.1%

chi-square test = 5.1, p value < 0.05 (significant)

Table 18

Cross tabulation of ICT and ELISA for IgG

<table>
<thead>
<tr>
<th>ICT</th>
<th>ELISA</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>Positive</td>
<td>51</td>
<td>3</td>
</tr>
<tr>
<td>Negative</td>
<td>14</td>
<td>282</td>
</tr>
<tr>
<td>Total</td>
<td>65</td>
<td>285</td>
</tr>
</tbody>
</table>

Sensitivity 81.3%, Specificity 98.9%, PPV 94.1%, NPV 96.32%

chi-square test = 41.3, p value < 0.001 (significant)
Chart 1
Seropositivity of Dengue

Chart 2
Age & Sex wise Distribution of Dengue Positive Cases
Chart 3
Seasonal Distribution of Dengue Positive Cases from 2011 to 2012

Chart 4
Clinical presentation of Dengue Positive Cases
Chart 5
Clinical Classification based on WHO Guidelines

Chart 6
Association of Platelet, WBC, Hematocrit with DF, DHF and DSS
Chart 7
Serological Categorisation of Dengue Positive Cases

Chart 8
Primary dengue based on duration of fever and serological markers
Chart 9
Secondary Dengue based on duration of fever and serological markers.

Table 10
Detection of NS1, IgM & IgG by ICT and ELISA
Chart 11
Sensitivity, Specificity, PPV & NPV of ICT for NS1, IgM, IgG
DISCUSSION

In order to provide timely information for the management of patients with acute dengue and effectively control dengue outbreaks, it is important to establish an accurate confirmation of acute dengue infection during the first few days of clinical symptoms.

For a long time, detection of dengue specific IgM/IgG has been the mainstay of diagnosis of Dengue infection. The Dengue specific IgM antibodies begin to appear only around fifth day of primary infection. The New parameter called NS1 now available can be detected from the first day of illness. Dengue NS1 is detected in the blood circulation as early as viral RNA detected in PCR.

In this study the seropositivity of dengue infection was 30%. In a study by Halstead et al\textsuperscript{52} 1969, Bangkok 29% of febrile illness was associated with dengue virus infection similar to this study.

In a study by Chakravarti A et al\textsuperscript{53} 2011, New Delhi conducted on 145 samples noted seropositivity of 60.7% which is higher to this study.

In this study 62.3% of the affected populations were males and 37.7% were females. The following studies were found to coincide with this study Aisha

In contrast to this study females were affected more than males in a study by Murray smith and Skelly C Queensland. But Susan shepherd et al in a study conducted at Pennisylvania showed that dengue infection can occur irrespective of sex.

In this study Male: female ratio was 1.6:1 and this is due to males being engaged in outdoor activities and due to their dressing culture when compared to females which increases the exposure to mosquito bites. The studies by Eng Eong Ooi 2001 Singapore, Shrivastava et al 2011 and Rajoo Singh Chhina et al 2008 Punjab had similar M: F ratio.

In this study the commonest age group affected was 0-10 years (42.05%) in both sexes. Increased incidence of infection in 0-10 years in this study is due to increased mosquito bite exposure in the school premises during the day time. The study by Shah GS et al Kathmandu revealed that the commonest age group affected in their study was from 8months to 14 years and Malavige et al 2004 Srilanka study showed age range from 1 month to 12 years which is similar to this study.
In a study by Anita chakravarti et al conducted at New Delhi the age group commonly affected was 26-30 years which is in contrast to this study.

In this study incidence of dengue cases were more during the months of November & December 2011 and January, May, June, July of 2012. Increase in the incidence of Dengue cases occur usually during rainfall. Tamilnadu receives rainfall from October to November followed by post monsoon period of December & January. The cause for the incidence of cases during the above months like May, June and July in this study is that the eggs can survive even in stored waters in the absence of rainfall. According to NVBCDP 2007 every year there is an upsurge in the cases of Dengue /DHF from July to November. Ekta gupta et al 2006 in their 3 year study had shown an increase in incidence during Post monsoon period (September – November).

A study by Louise Kelly –hope Mandeleine C. Thomson 2008 in their Study revealed that a climatic change has a role in the transmission of Dengue. Umesh Isalkar 2009 said that whether changes cause atypical viral fever.

In this study the commonest symptom was fever100% followed by headache 60.7%, Myalgia 38.3%, arthralgia 29.9% ,abdominal pain 28.3%
Saadiah Sulaiman et al \(^{67}\) 1999 in their study had fever of 100% followed by headache (80.9%) arthralgia (74%), myalgia (70%), rash (4.6%) and vomiting (62.7%) similar to this study. Jonathon et al \(^{68}\) 2010 in their study had fever (72%) as most common symptom followed by epistaxis, abdominal pain and rashes.

Rahman et al \(^{69}\) 2002 in their study had headache (90%) as predominant symptom followed by myalgia / arthralgia (85%) and vomiting (64%).

In this study Dengue positive cases were classified according to WHO guidelines. It showed 48.5% Dengue fever, 49.5% Dengue haemorrhagic fever and 2% Dengue shock syndrome. In this study DHF is found to be high because of increased incidence of infection in children. Because of the increased surface area of the blood vessel per unit volume of skeletal muscle and the immature blood vessel leading to increased vascular permeability, DHF is common in children. Even though Dengue haemorrhagic fever was high in this study and is said to be a complication of secondary dengue, DSS was comparatively less because of the eminent care and management given to the diagnosed cases in the respective wards.

In a study by S Kalyanaroj et al \(^{70}\) 1997 Thailand, conducted on 60 seropositives showed 53% (32) Dengue fever, 47% (28) Dengue
haemorrhagic fever and Dengue shock syndrome. According to David W. Vaughn and Sharone Green fatality rate is decreased in DHF/DSS cases those who are hospitalised and treated promptly.

In this study thrombocytopenia was observed in 90% of the positive cases the common range was between 51,000-1 lakh followed by 20,000- 40,000. Thrombocytopenia is due to decreased platelet production in Dengue fever and increased peripheral destruction in DHF. RD Kulkarni et al 2011 Karnataka, in their study had thrombocytopenia associated with majority of dengue positive cases than dengue negative cases similar to this study. In a study by Chandrakanta et al 2008 revealed 60% of thrombocytopenia < 1lakh.

Karande et al 2005 revealed that arthralgia and thrombocytopenia if present in a child increases the chance of the child to be Dengue positive. But a study by Col Banerjee et al revealed that thrombocytopenia may not always be a feature of Dengue.

In this study leucopenia was observed in 79/107(73.8%) of dengue positive cases. Out of 79, 37 were associated with dengue fever, 40 were associated with Dengue haemorrhagic fever, 2 were associated with Dengue shock syndrome. The association of leucopenia with Dengue fever, DHF and DSS is
71.1%, 75.4% and 100% respectively (Table 9). Neutrophil adhesion to dengue infected endothelial cell is one of the causes for leucopenia.

**Kalyanarooj et al** 70 1997 has stated that leucopenia in Dengue is due to bone marrow suppression. In a study by **Somchai Insiripong MD** 75 2010 revealed that leucopenia in DHF is multifactorial.

In this study elevated Hematocrit (>45%) was observed in 33 patients, 5 were associated with dengue fever, 26 were associated with Dengue haemorrhagic fever and 2 were associated with Dengue shock syndrome. The association of elevated HCT with DF, DHF and DSS are 9.6%, 49.05% and 100% respectively. Rise in haematocrit is due to increased vascular permeability and plasma leakage in DHF/DSS. **Malavige et al** 76 2007 in their study have considered hemoconcentration when the packed cell volume was >45 in children.

In this study liver enzymes like AST (Aspartate aminotransferase) and ALT (Alanine aminotransferase) were elevated in 28 and 24 patients respectively. Among ALT and AST rise, >40 units majority were associated with DHF and DSS. **Rajoo Singh Chhina et al** 60, Punjab in their study had significant rise of AST (97%) and ALT (93%) in DHF/DSS as compared to
DF. They also concluded that raised AST can be an early indicator of dengue infection.

In secondary dengue causing liver damage AST will be elevated more than ALT which is due to the release of AST from damaged monocytes of dengue infection and due to release of AST from skeletal muscles due to myalgia.

In this study, the Ultrasound findings showed more of Gall bladder thickening followed by pleural effusion, ascites and hepatomegaly. Gall bladder thickening is due to increased vascular permeability where the fluid tends to collect in between the layers increasing the thickness of the Gall bladder which occurs in Dengue haemorrhagic fever and Dengue shock syndrome. Similarly the fluid collects in pleural and peritoneal cavity.

In the study conducted by Bala subramanian et al 2006 ultrasonography was found to be superior to radiography in detecting pleural effusion. In the study by Kumar et al 2010 Karnataka, pleural effusion was noted in 4.29 % (20) of 466 patients which is less than this study. In this study by Zulkarnain 2004 revealed 29.8% of Gall bladder edema which is higher than this study.
In this study the incidence of Primary dengue was 48(44.8%) and Secondary Dengue was 59(55.1%) in the proportion of 0.8:1. In a study by Jonathan G et al 2010 secondary dengue (81%) was more than primary dengue which is similar to this study. In a study by Neeraja M et al 22, Hyderabad showed 72.5% of secondary dengue conducted on 211 patients which is similar to this study.

In 48 samples of primary dengue NS1 showed higher positivity (56.25%) followed by IgM alone positivity of 18.75%, NS1 & IgM positivity of 16.6%, and IgM & IgG positive with ratio > 1 of 8.33%. During the primary infection, NS1 gets secreted out from virus infected cells which indicates underlying viremia and pathogenesis of infection. As there are low antibody titres in primary dengue, the NS1 protein can be estimated more in serum during the acute period. So NS1 detection can be used as a stand alone test for Primary dengue in cases when IgM is not detectable and where PCR is not available.

During the acute period of 1-5 days in primary dengue, NS1 detection (72.9%) had higher positivity followed by NS1 & IgM(21.6%) and IgM alone positive of 2(5.4%). As IgM antibodies tends to appear after 4-5 days of infection and as many patients in this study presented within 5 days, the
sensitivity of NS1 & IgM. IgM alone positive in primary dengue were less when compared to NS1 positivity alone. Hence when IgM ELISA is negative in the acute period, NS1 ELISA should be done for diagnosis which significantly improves the detection rate without the requirement of paired serum to demonstrate the rise in titre of antibodies. In a study by Chakravarti A, Kumar A, Malik S\textsuperscript{53} 2011 New Delhi conducted on 145 acute serum samples NS1 ELISA showed a positivity rate of 65.9% and MAC-ELISA showed 60.2% positivity in the acute period. Veasna duong et al\textsuperscript{9} study also showed NS1 positivity to be higher in first 3 days. Minipritam singh et al\textsuperscript{80} and Chua KB et al\textsuperscript{81} 2011 studies revealed that NS1 antigen capture ELISA was more sensitive than RT-PCR and viral isolation.

During the early convalescent period of 6-10 days in primary dengue, IgM showed higher positivity (70%) than other serological markers. This is due to the appearance of IgM antibodies after 4\textsuperscript{th} day of illness and is the first antibody to appear following Dengue infection. IgM antibody gradually increases towards end of first week and it persists for 3 months thereafter. The virus may be at undetectable levels in this period as they tend to be in complex with IgM antibody. Hence NS1 positivity was less during this
period. IgM and IgG combination also showed less positivity (30\%) during this period as anti dengue IgG is detectable only at low titer during this period as it appears still later. In a study by S Datta and Wattal IgM detection by MAC ELISA showed 93.6\% positivity in early convalescent period.

In more than 10 days duration, IgM & IgG positive with ratio > 1 showed higher positivity (100\%) as IgG antibodies would have appeared during this period which increases further in the proceeding weeks and persists lifelong thereafter.

In this study, in secondary dengue, IgM and IgG positive with ratio < 1 showed higher positivity (64.4\%) than other parameters followed by NS1, IgM and IgG combination (23.7\%). As the antibody titres rise extremely rapidly, IgM and IgG are detected more in secondary dengue.

During the acute period of 1-5 days in secondary dengue NS1, IgM and IgG combination showed higher positivity (47.8\%) than IgM & IgG combination 6 (26.08\%), NS1 & IgG 1 (4.3\%) and IgG alone positive with thrombocytopenia 5 (21.7\%). The NS1 antigen has reduced sensitivity in secondary dengue because it is sequestered in immune complexes and that target epitopes are not accessible to the plate bound mAb in NS1 ELISA.
High levels of IgG are detectable even in acute phase of secondary dengue due to previous infection and rise dramatically over the proceeding 2 weeks whereas IgM levels tend to be significantly lowered in secondary infection.

In the early convalescent period of 6-10 days in secondary dengue IgM & IgG positive with ratio < 1 22 (84.6%) showed higher positivity as IgM to second infection appears during this period. NS1, IgM & IgG showed positivity of 3 (11.5%), IgG alone positive with thrombocytopenia 1 (3.8%). As IgG is present in both current and past infections, presence of IgG alone does not indicate active infection. Hence it should be combined with platelet count. Only if the platelet count is lowered it indicates current infection. If it is normal, it shows past infection.

In more than 10 days duration of secondary dengue IgM & IgG positive with ratio < 1 showed higher positivity (100%) which is due to the presence of IgM & IgG antibodies to the second infection. Susana vazquez et al 2007 showed that IgM and IgG capture ELISA kits has high sensitivity and specificity and offers good alternative for dengue diagnosis.
ICTs for the detection of NS1, IgM, IgG antibodies have been developed by a number of commercial companies and have found wide applications because of their ease of use and rapidity of results.

The case detection by ICT in this study was 10.2% for NS1, 17.7% for IgM, 15.4% for IgG, whereas in ELISA it was 14.2%, 20.8% and 18.2% respectively. This clearly shows that case detection was more in ELISA. The ICT is found to be less sensitive to ELISA and gives false negative results in some cases. Cross reaction with other flaviviruses gives rise to false positives in some cases. In a study by RD Kulkarni et al in 2011 showed NS1 positivity 29%, IgM positivity 50% and IgG positivity 2.8% in ICT.

Masao et al in their study in 2011 in Japan had said that NS1 rapid test is suitable for lab diagnosis due to its reliability and rapidity as it require only 20 minutes for detection. But in view of its low sensitivity it is not suitable for screening purposes.

In a study by Subhash C Arya in 2011 the ICT was highly sensitive (88%) and specific (98%).

As diagnostic assays are usually evaluated in terms of Sensitivity and specificity that was calculated by 2x2 cross-tabulation, using a reference
standard (the test most widely used) is compared to determine diagnostic accuracy.

Using ELISA as reference standard, the accuracy indices of the ICT were calculated.

NS1 ICT had a sensitivity of 68%, specificity 99.3%, PPV 94.4%, NPV 85.7%. Using chi-square test, p value of <0.001 was obtained which was found to be statistically significant. In a study by Subhash C Arya et al\textsuperscript{85} 2011 ICT showed 80-90% detection rate during first 7 days. In a Study by Vu Ty Han et al\textsuperscript{10}, Thailand NS1 LFRT was found to be 100% specific and 72% sensitive in primary than secondary dengue.

In this study the sensitivity and specificity of IgM by ICT was 80.8% & 98.9%, PPV-95.1% & NPV-95.1%. Using chi-square test, p value of <0.05 was obtained for IgM which was found to be statistically significant.

In a study by M Moorthy et al\textsuperscript{16} 2009 showed that the accuracy indices of ICT for IgM were 81.8%, 75.0%, 61% and 89.6% and concluded that ICT not to be used as stand alone test.

In this study IgG in ICT showed Sensitivity of 81.3%, specificity 98.9%, PPV 94.1% & NPV 96.32% Using chi-square test, p value of <0.001 was
obtained which was found to be statistically significant. Moorthy et al\textsuperscript{16} 2009 study with sensitivity of 87.5\%, specificity 66.6\%, PPV 72\%, NPV 83.9\% concluded that ICT with moderate performance could not be used as stand alone test.

WHO’s multicentric evaluation of Dengue antibody ICTs had IgM sensitivity from 20\% to 100\% & specificity from 77\% to 98\% when compared with reference ELISA.

- Most of the patients were referred from various places and would have received few days treatment before reaching the hospital. The precise day of fever at the time of conducting the test could not be obtained in a large no of cases. In spite of this, NS1 alone was positive in 25\% cases in this study.
SUMMARY

- Seropositivity of Dengue in 350 suspected cases during the study period was 30%.

- The commonest age group affected by Dengue in this study was 0-10 years in both sexes.

- Dengue was predominant in Males when compared to Females with the ratio of 1.6:1.

- Dengue incidence in this study was more during the months of November, December 2011, January, May, June, July of 2012.

- Of all the symptoms, fever was the commonest symptom followed by headache, myalgia, arthralgia, abdominal pain, vomiting, oliguria and rash.

- Melena was the commonest bleeding manifestation followed by bleeding gums, hemetemesis and epistaxis in this study.

- Dengue positive cases were classified into Dengue fever (48.5%), Dengue haemorrhagic fever (49.5%) and Dengue shock syndrome (2%) based on WHO guidelines.
• In the haematological parameters, Thrombocytopenia was associated more with Dengue positive cases. Platelet count of 50,000- 1 lakh was commonest range and majority were associated with DHF&DSS.

• WBC count of <4000 was more commonly associated with DHF and DSS

• Elevated Haematocrit level >45 was associated with DHF/DSS.

• Biochemical parameters- AST and ALT were elevated in DF, DHF and DSS.

• Of the USG findings, Gall bladder thickening, pleural effusion and ascites were seen in majority of Dengue haemorrhagic fever and Dengue shock syndrome.

• In this study the incidence of secondary dengue(55.1%) was more than primary dengue(44.9%) with the ratio of 0.8:1

• NS1 positivity was high in primary dengue followed by IgM alone.

• In the acute period of 1-5 days in primary dengue NS1 antigen positivity was found to be higher followed by NS1 & IgM.

• In the early convalescent period (6-10days) of Primary dengue IgM alone had higher positivity followed by IgM &IgG positive with ratio >1.
In the late convalescent period (10 days) of primary dengue, IgM & IgG positive with ratio >1 alone showed positivity.

In secondary dengue, IgM & IgG positive with ratio <1 had higher positivity followed by NS1, IgM & IgG combination.

In the acute period of secondary dengue (1-5 days) NS1, IgM & IgG positive showed higher positivity followed by IgM, IgG positive with ratio <1, IgG alone positive with thrombocytopenia and lowered NS1 & IgG positivity.

In the early convalescent period (6-10 days) IgM & IgG positive with ratio <1 showed higher positivity followed by the combination of NS1, IgM, IgG.

In late convalescent period (>10 days) IgM & IgG positive with ratio <1 alone showed higher sensitivity.

Case detection rate of ICT was 26.2% and ELISA was 30.5% for 350 cases.

The percentage of case detection by ICT for all the 3 parameters NS1, IgM and IgG was 10.2%, 17.7% and 15.4% and ELISA showed 14.2%, 20.8% and 18.2%.
• Sensitivity, Specificity, PPV and NPV for NS1 in ICT were 68%, 99.3%, 94.4% and 85.7%.

• Sensitivity, Specificity, PPV and NPV of IgM in ICT were 80.8%, 98.9%, 95.1% and 95.1%.

• Sensitivity, Specificity, PPV and NPV of IgG in ICT were 81.3%, 98.9%, 94.1% and 96.32%. 
CONCLUSION

As per the results of this study NS1 ELISA is highly sensitive and proved to be a valuable tool in the diagnosis of dengue particularly in the acute period. NS1 is a reliable marker in primary dengue and when combined with IgM improves the detection rate significantly in a single serum sample in the absence of paired sera.

For diagnosis of Dengue infection irrespective of duration of fever all the three (i.e) NS1, Dengue IgM and IgG by ELISA must be done. This helps to rule out infection and to avoid false negatives. Immuno capture ELISA is highly sensitive in the detection of dengue cases.

Considering the moderate performance of ICT in this study the device cannot be used as a stand alone test and it should always be supplemented by ELISA for the diagnosis of Dengue infection.

Serological differentiation of primary and secondary can be arrived as per the results of the study as shown below
<table>
<thead>
<tr>
<th>NS1</th>
<th>IgM</th>
<th>IgG</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>-</td>
<td>-</td>
<td>Primary dengue</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>-</td>
<td>Primary dengue</td>
</tr>
<tr>
<td>-</td>
<td>+</td>
<td>-</td>
<td>Primary dengue</td>
</tr>
<tr>
<td>-</td>
<td>+</td>
<td>+</td>
<td>Primary dengue (IgM/IgG ratio &gt; 1)</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>+</td>
<td>Past infection (Plateletcount &amp; Total count normal)</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>+</td>
<td>Secondary dengue (Platelet/Total count low)</td>
</tr>
<tr>
<td>+</td>
<td>-</td>
<td>+</td>
<td>Secondary dengue</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Secondary dengue</td>
</tr>
<tr>
<td>-</td>
<td>+</td>
<td>+</td>
<td>Secondary dengue (IgM/IgG ratio &lt; 1)</td>
</tr>
</tbody>
</table>

Significant association of haematological profile and biochemical profile with seropositives in this study insists that these tests should be considered and given importance in the diagnosis and management of dengue.

In conclusion, based upon the higher positivity of the NS1 ELISA both in primary and secondary dengue, this study gains public health importance because it suggests that NS1 antigen should be included along with routinely used antibody testing protocols for early detection and management of cases. ELISA is preferable for diagnostic purposes compared to ICT and the use of
Immunocapture ELISA in the test panel for dengue will reduce the false Negativity thereby reducing the morbidity and mortality rate.
1. Mandell’s, Douglas and Bennett’s principle and practice of infectious disease. 7th edition. Vol. 2


5. Sukathida Ubol, Promsin musrinoul, Jeerayut chaijaruwanich et al Differences in Global gene expression in peripheral blood mononuclear cells indicate a significant role of the innate responses in progression of Dengue fever but not Dengue haemorrhagic fever. The Journal of infectious Diseases 2008; 197:1459-67


8. Tamilarasu kadhiravan et al. Association of intracellular Th1-Th2 balance in CD4+ T cells and MIP-1α in CD8+ T cells with disease severity in adults with Dengue.


13. Dr.Vijay N.,Yewae,Dr.Sitara Gopinathan Dengue fever IAP speciality series (paediatric infectious Diseases ,Under IAP Action plan 2006)


17. Harrison’s textbook of infectious diseases. 16th Edition


29. Ampaiwan Chuansumrit, MD and Kanchana Tangnararatrachakti, MD. *Transfusion* alternatives in transfusion medicine January 2005


37. Rosannito peeling et al. NS1 can be detected in patients with proven secondary dengue upto 9 days after the onset of illness. Nature reviews Microbiology. References S30-37.


40. Clinical And Laboratory Guidelines for Dengue fever and Dengue haemorrhagic fever / Dengue shock Syndrome for Health care providers. Caribbean Epidemiology center (CAREC), PanAmerican health organization , World Health organization.


44. Maria G. Guzman, Scott B Halstead, Harvey Attsob, philippe bruchy Dengue a continuing global threat. Nature Reviews Microbiology.

45. GN Malavige, S Fernando DJ Fernando et al Dengue viral infections Post graduate medical journal 2004;80:588-601

47. Sanofi-pasteur and international vaccine institute partner against Dengue OCT 20, 2011.


52. Halstead SB, Nimmanitya S, Margitha MR. Dengue and Chikungunya virus infection in man in Thailand observation on Disease in output. AM J Tropical Med Hygiene 1969 18; 972-83 al


57. Susan Shepherd et al. Director of education of research, PENN Travel medicine, Dept of Emergency medicine, University of Pennsylvania Medical centre.


62. Anita chakravarti ,Amod kumar and Sonia malik Detection of dengue infection by combining the use of NS1 antigen based assay with antibody detection. Department of Microbiology Maulana Azad Medical college and associated LokNayak hospital, Bahadur shah, Zafar marg,NewDelhi.


64. Ekta gupta ,Lalit Das,Geetanjali kapoor and shoba broor Changing Epidemiology of dengue in Delhi ,India Virology journal 2006:3:92

65. Louise Kelly –hope Mandeleine C.Thomson climate and infectious disease Advances in global change research 2008: 30:p.no 31-70

66. Umesh ISalkar, TNN 2009 Weather changes cause atypical Viral fever


71. David W. Vaughn and Sharone green. Hunter’s Tropical medicine and Emerging infectious diseases, 8th Edition. 201:240-244


74. Lt Col M Banerjee, Lt Col T-Chatterjee, Lt col GS Choudhry, et al. Thrombocytopenia may not always be a feature of Dengue. VK Kataria Dengue: A clinicopathological profile 2008;64:333-386


80. Minipritam Singh, Manasi Mazumdar, Gagandeep Singh et al. NS1 antigen as an early diagnostic marker in dengue: report from India. Diagnostic Microbiology & Infectious Diseases 2010;68:1:p.50-54


APPENDIX - 1

NS1 ELISA

**Sample dilution:** 75 µl sample diluent + 75 µl of sample (1 in2)

**Control dilution:** NC&PC diluted in the same ratio.

**Calibrator is also** diluted in the same ratio as above in triplicate.

**Wash buffer (20x):** 19 parts of distilled water added to 1 part of wash buffer concentrate. Quantity prepared depending upon the strips used for the test.

IgM ELISA

**Serum pre dilution:** Suitable test tubes used for dilution of serum, NC, PC, and CO . **Wash buffer dilution:** 19 parts of distilled water is mixed with 1 part of wash buffer concentrate. The required quantity is used and the remaining is discarded

**Sample dilution:** 5µl Sample diluted with 500µl of sample diluent (1:100)

**Control dilution:** NC, PC and cutoff calibrator diluted in the same manner as sample.
IgG ELISA

**Serum pre dilution:**

1. Serum 10µl + serum diluent 1000µl (1:100 dilution) done using suitable test tubes.

2. Positive control, negative control and calibrators diluted in the same manner

**Wash buffer dilution:** One Part of buffer concentrate added to 19 parts of distilled water. Total volume prepared as required for the procedure.
## APPENDIX-2

**Immunochromatography card Test (n=107)**

<table>
<thead>
<tr>
<th>Fever duration</th>
<th>NS1 alone</th>
<th>IgM alone</th>
<th>IgG</th>
<th>NS1+IgM</th>
<th>IgM+IgG</th>
<th>NS1 +IgG</th>
<th>NS1+IgM+IgG</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-5 Days (60)</td>
<td>20</td>
<td>4</td>
<td>1</td>
<td>6</td>
<td>11</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>6 – 10 Days (36)</td>
<td>0</td>
<td>7</td>
<td>2</td>
<td>1</td>
<td>25</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>&gt; 10 Days (11)</td>
<td>0</td>
<td>1</td>
<td>4</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>20</strong></td>
<td><strong>12</strong></td>
<td><strong>7</strong></td>
<td><strong>7</strong></td>
<td><strong>39</strong></td>
<td><strong>3</strong></td>
<td><strong>4</strong></td>
</tr>
</tbody>
</table>
# LIST OF TABLES

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Seropositivity of Dengue</td>
</tr>
<tr>
<td>2</td>
<td>Age and sex wise distribution of dengue positive cases</td>
</tr>
<tr>
<td>3</td>
<td>Seasonal distribution of dengue positive cases</td>
</tr>
<tr>
<td>4</td>
<td>Clinical presentation of dengue positive cases</td>
</tr>
<tr>
<td>5</td>
<td>Clinical classification based on WHO Guidelines</td>
</tr>
<tr>
<td>6</td>
<td>Platelet count in Dengue positive cases</td>
</tr>
<tr>
<td>7</td>
<td>WBC count of Dengue positive cases</td>
</tr>
<tr>
<td>8</td>
<td>Level of haematocrit in Dengue positive cases</td>
</tr>
<tr>
<td>9</td>
<td>Association of platelet, HCT and WBC count with DF,DHF and DSS</td>
</tr>
<tr>
<td>10</td>
<td>ALT and AST levels in Dengue positive cases</td>
</tr>
<tr>
<td>11</td>
<td>USG findings in Dengue positive cases</td>
</tr>
<tr>
<td>12</td>
<td>Serological Categorisation of Dengue positive cases</td>
</tr>
<tr>
<td>13</td>
<td>Primary Dengue based on duration of fever and serological markers.</td>
</tr>
<tr>
<td>14</td>
<td>Secondary dengue based on duration of fever and serological markers.</td>
</tr>
<tr>
<td>15</td>
<td>Case detection by ICT and ELISA</td>
</tr>
<tr>
<td>15a</td>
<td>Case detection by ICT and ELISA for individual parameters</td>
</tr>
<tr>
<td>16</td>
<td>Cross tabulation of ICT and ELISA for NS1</td>
</tr>
<tr>
<td>17</td>
<td>Cross tabulation of ICT and ELISA for IgM</td>
</tr>
<tr>
<td>18</td>
<td>Cross tabulation of ICT and ELISA for IgG</td>
</tr>
</tbody>
</table>
# LIST OF CHARTS

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Seropositivity of Dengue</td>
</tr>
<tr>
<td>2.</td>
<td>Age and sex wise distribution of Dengue positive cases</td>
</tr>
<tr>
<td>3.</td>
<td>Seasonal distribution of Dengue positive cases</td>
</tr>
<tr>
<td>4.</td>
<td>Clinical presentation of Dengue positive cases</td>
</tr>
<tr>
<td>5.</td>
<td>Clinical classification of Dengue positive cases</td>
</tr>
<tr>
<td>6.</td>
<td>Association of platelet, HCT and WBC count with DF,DHF and DSS</td>
</tr>
<tr>
<td>7.</td>
<td>Serological Categorisation of Dengue positive cases</td>
</tr>
<tr>
<td>8.</td>
<td>Primary dengue based on duration of fever and serological</td>
</tr>
<tr>
<td></td>
<td>markers</td>
</tr>
<tr>
<td>9.</td>
<td>Secondary Dengue based on duration of fever and serological</td>
</tr>
<tr>
<td></td>
<td>markers</td>
</tr>
<tr>
<td>10.</td>
<td>Case detection by ICT and ELISA for NS1,IgM ,IgG</td>
</tr>
<tr>
<td>11.</td>
<td>Sensitivity ,specificity ,PPV and NPV of ICT for NS1,IgM,IgG</td>
</tr>
</tbody>
</table>
# LIST OF COLOUR PLATES

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Dengue Duo combo card kit</td>
</tr>
<tr>
<td>2</td>
<td>Dengue NS1 antigen positive</td>
</tr>
<tr>
<td>3</td>
<td>Dengue NS1antigen with IgM antibody positive</td>
</tr>
<tr>
<td>4</td>
<td>Dengue NS1antigen with IgM &amp; IgG antibody positive</td>
</tr>
<tr>
<td>5</td>
<td>Dengue NS1antigen with IgG antibody positive</td>
</tr>
<tr>
<td>6</td>
<td>NS1 antigen negative , IgM &amp; IgG antibody positive</td>
</tr>
<tr>
<td>7</td>
<td>IgM antibody positive</td>
</tr>
<tr>
<td>8</td>
<td>IgG antibody positive</td>
</tr>
<tr>
<td>9</td>
<td>Dengue NS1 ELISA kit</td>
</tr>
<tr>
<td>10</td>
<td>Dengue IgM ELISA kit</td>
</tr>
<tr>
<td>11</td>
<td>Dengue IgG ELISA kit</td>
</tr>
<tr>
<td>12</td>
<td>ELISA reader</td>
</tr>
<tr>
<td>13</td>
<td>Antigen and antibody mixture of IgM &amp;IgG ELISA</td>
</tr>
<tr>
<td>14</td>
<td>Microtitre plate with samples</td>
</tr>
<tr>
<td>15</td>
<td>Microtitre plate with samples after substrate addition</td>
</tr>
<tr>
<td>16</td>
<td>Samples after addition of stop solution</td>
</tr>
</tbody>
</table>
LIST OF ABBREVIATIONS

ADE- Antibody dependent enhancement
ALT- Alanine aminotransferase
AST- Aspartate aminotransferase
Bcell- B lymphocyte
C3a, C5a- complement factors
CFT- Complement fixation test
DEN – Dengue
DENV- Dengue virus
DF- Dengue fever
DHF- Dengue haemorrhagic fever
DSS- Dengue shock syndrome
ELISA- Enzyme linked immunosorbent assay
GB thickening- Gallbladder thickening
HCT- Haematocrit
HAI- Haemagglutination inhibition
HRP- Horse radish peroxidase
IgM- Immunoglobulin M
IgG- Immunoglobulin G
IFN- Interferon
IL- Interleukin
ICT- Immunochromatography
Mab- Monoclonal antibody
NASBA-Nucleic acid sequence based amplification
NT- neutralization
NS1- Nonstructural protein
NPV-Negative predictive value
PPV- Positive predictive value
PD-Primary dengue
RT-PCR- Reverse transcriptase polymerase chain reaction
RANTES- Regulated on activated normal T cell expressed and secreted
SPSS- Statistical package for social sciences
SD-Secondary dengue
T cell- T lymphocyte
TNF- Tumour necrosis factor
TMB- Tetramethylbenzidine
USG- Ultrasonogram
PROFORMA

Date:

Name of the patient: Age / sex:

Ward: ID no:

Occupation: Present address:

Date of admission:

Permanent address:

H/o present illness:

Fever:
  o Onset
  o Duration
  o Type of fever
    o Associated with rash/ myalgia/ arthralgia /abdominal pain/vomiting/headache
  o Bleeding tendencies

H/O past illness:
  - Travel to endemic areas.
  - Previous h/o fever with hospitalization
  - Living in endemic areas.

Any relevant investigations done outside:

H/O treatment:

Nature of specimen collected:

Date of collection:

Investigation done:
Selected Fever Cases

Blood samples collected & received in Laboratory

Rapid card test
- Dengue specific Antigen
- Dengue Specific IgM & IgG Antibodies

ELISA
- Dengue specific Antigen
- Dengue Specific IgM & IgG Antibodies

Hematological Markers
1. Platelet count
2. Packed cell volume
3. Total Leucocyte count

Biochemical Markers
1. SGOT
2. SGPT
WORKSHEET

Collect Blood Samples from selected Cases

Separate serum by Centrifugation

Subject to both ICT and ELISA

Categorise ELISA Positive cases into $1^\text{st}$ and $2^\text{nd}$ dengue

Compare Case detection by ELISA and ICT for serological markers

Calculate Sensitivity, specificity, PPV, NPV for ICT using ELISA as Reference

Collect clinical data, hematological and biochemical profile for correlation
CONSENT FORM

Dr P.Malini, Post Graduate student in the Department of Microbiology, Coimbatore Medical College, Coimbatore, is studying on ‘Multivariate Analysis of Dengue in a Tertiary care Hospital’ regarding.

I am, ___________________________ of age _____ years, sex - M/F, have been explained about the study. The venepuncture procedure, the risk involved and complications of the procedure were explained to me in my mother tongue. I have also been explained that the data obtained herein may be used for research and publication. I whole heartedly give my consent to participate in the study.

Place:

Date:                  Signature
<table>
<thead>
<tr>
<th>S.No.</th>
<th>IP /OP</th>
<th>Name</th>
<th>Age</th>
<th>Sex</th>
<th>Presenting Complaints</th>
<th>Platelet</th>
<th>WBC</th>
<th>HCT</th>
<th>ALT</th>
<th>AST</th>
<th>USG</th>
<th>ELISA</th>
<th>NS1</th>
<th>IgM</th>
<th>IgG</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>69212</td>
<td>Saraswathi</td>
<td>28</td>
<td>F</td>
<td>Fr - 10 days, AbdPain 5 days, arthralgia, myalgia</td>
<td>20,000</td>
<td>3000</td>
<td>17.2</td>
<td>28</td>
<td>30</td>
<td>Normal</td>
<td>N</td>
<td>P</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>2</td>
<td>70201</td>
<td>Karthick</td>
<td>16</td>
<td>M</td>
<td>Fr - 4 days, myalgia, headache</td>
<td>56,000</td>
<td>3000</td>
<td>38.7</td>
<td>27</td>
<td>29</td>
<td>Normal</td>
<td>N</td>
<td>P</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>3</td>
<td>73576</td>
<td>Rajkumar</td>
<td>33</td>
<td>M</td>
<td>Fr - 12 days, Hematemesis, Haematuria, myalgia, rash</td>
<td>23,000</td>
<td>3200</td>
<td>53.7</td>
<td>52</td>
<td>72</td>
<td>BILPE</td>
<td>N</td>
<td>P</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>4</td>
<td>73482</td>
<td>Ganesh</td>
<td>5</td>
<td>nch</td>
<td>Fr - 5 days, vomiting, rash</td>
<td>33,000</td>
<td>2000</td>
<td>45.5</td>
<td>25</td>
<td>27</td>
<td>Normal</td>
<td>N</td>
<td>p</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>5</td>
<td>73486</td>
<td>Sangamithra</td>
<td>4</td>
<td>fch</td>
<td>Fr - 10 days, Melena 2 days, headache</td>
<td>56000</td>
<td>3500</td>
<td>34.8</td>
<td>21</td>
<td>25</td>
<td>min PE GB thickening</td>
<td>N</td>
<td>p</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>6</td>
<td>73561</td>
<td>Elango</td>
<td>11</td>
<td>nch</td>
<td>Fr - 2 days, Arthralgia</td>
<td>43000</td>
<td>3000</td>
<td>24</td>
<td>25</td>
<td>27</td>
<td>Normal</td>
<td>P</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>7</td>
<td>73506</td>
<td>Vijaya</td>
<td>60</td>
<td>F</td>
<td>Fr - 10 days, Altered sensorium, arthralgia, myalgia</td>
<td>89000</td>
<td>16100</td>
<td>32.7</td>
<td>45</td>
<td>89</td>
<td>Grade I MKD</td>
<td>N</td>
<td>P</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>8</td>
<td>113</td>
<td>Sumaiya</td>
<td>5</td>
<td>fch</td>
<td>Fr - 12 DAYS, Melena 3 episodes, rash, epistaxis</td>
<td>43000</td>
<td>3400</td>
<td>25</td>
<td>28</td>
<td>30</td>
<td>GB wall thickening, min. R PE</td>
<td>N</td>
<td>p</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>9</td>
<td>351</td>
<td>Divyadharshni</td>
<td>21/2</td>
<td>fch</td>
<td>Fr - 7 days, Headache, melena</td>
<td>13000</td>
<td>3600</td>
<td>27.3</td>
<td>97</td>
<td>142</td>
<td>hepatomegaly</td>
<td>N</td>
<td>p</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>10</td>
<td>795</td>
<td>Sanfiya</td>
<td>8</td>
<td>fch</td>
<td>Fr - 6 days, Myalgia, vomiting, rash, epistaxis</td>
<td>91000</td>
<td>3000</td>
<td>23.3</td>
<td>31</td>
<td>32</td>
<td>Normal</td>
<td>N</td>
<td>P</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>11</td>
<td>941</td>
<td>Sanjay</td>
<td>8</td>
<td>mch</td>
<td>Fr - 7 days, Abdmn Pain, myalgia</td>
<td>19000</td>
<td>6000</td>
<td>24.7</td>
<td>33</td>
<td>35</td>
<td>GB wall thickening, R PE</td>
<td>N</td>
<td>p</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>12</td>
<td>1041</td>
<td>Abbas ali</td>
<td>14</td>
<td>M</td>
<td>Fr - 1 week, Abdmn Pain 3 days, Vomiting 1 week, Bleeding gums</td>
<td>237000</td>
<td>3100</td>
<td>46</td>
<td>23</td>
<td>27</td>
<td>Mod. ascites</td>
<td>N</td>
<td>p</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>No.</td>
<td>ID</td>
<td>Name</td>
<td>Age</td>
<td>Sex</td>
<td>Symptoms</td>
<td>Days</td>
<td>WBC</td>
<td>RBC</td>
<td>Hb</td>
<td>Platelets</td>
<td>Platelets%</td>
<td>GB thickening</td>
<td>RPE</td>
<td>SE</td>
<td>DF</td>
</tr>
<tr>
<td>-----</td>
<td>------</td>
<td>-------------</td>
<td>-----</td>
<td>-----</td>
<td>--------------------------------</td>
<td>------</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----------</td>
<td>------------</td>
<td>---------------</td>
<td>-----</td>
<td>----</td>
<td>----</td>
</tr>
<tr>
<td>13</td>
<td>548</td>
<td>Ajith</td>
<td>10</td>
<td>mch</td>
<td>Fr-6 days, Myalgia, bleeding gums</td>
<td>47000</td>
<td>2800</td>
<td>27.6</td>
<td>37</td>
<td>39 Normal</td>
<td>p</td>
<td>N p P SEC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>2236</td>
<td>Mohammed Safix</td>
<td>14</td>
<td>M</td>
<td>Fr-3 days, Arthralgia, myalgia</td>
<td>52000</td>
<td>3500</td>
<td>43</td>
<td>41</td>
<td>43 Normal</td>
<td>p</td>
<td>N p P SEC DHF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>2767</td>
<td>Neelakandan</td>
<td>5</td>
<td>mch</td>
<td>Fr-5 days, Abdmn Pain 3 days, Oliguria</td>
<td>40000</td>
<td>3000</td>
<td>45.5</td>
<td>43</td>
<td>45 GB thickening</td>
<td>N</td>
<td>p P SEC DHF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>2512</td>
<td>Gowrav Kumar</td>
<td>11</td>
<td>mch</td>
<td>Fr-6 days, Abdmn Pain 2 days, Oliguria 3 days</td>
<td>56000</td>
<td>3600</td>
<td>51.1</td>
<td>47</td>
<td>49 GB thickening</td>
<td>N</td>
<td>p P SEC DF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>2805</td>
<td>Vanitha</td>
<td>18</td>
<td>F</td>
<td>Fr-5 days, Arthralgia</td>
<td>84000</td>
<td>7000</td>
<td>52</td>
<td>51</td>
<td>53 GB thickening</td>
<td>p</td>
<td>p P SEC DHF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>2930</td>
<td>Varsha</td>
<td>5</td>
<td>fch</td>
<td>Fr-6 days, Vomiting 3 episode, Abdmn Pain, Oliguria</td>
<td>35000</td>
<td>3900</td>
<td>46</td>
<td>55</td>
<td>57 GB thickening, RPE</td>
<td>N</td>
<td>p P SEC DSS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>4738</td>
<td>Maran</td>
<td>75</td>
<td>M</td>
<td>Abdmn Pain, Fr-2 days, myalgia</td>
<td>136000</td>
<td>2500</td>
<td>46</td>
<td>59</td>
<td>60 Normal</td>
<td>p</td>
<td>p P SEC DF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>4968</td>
<td>Vijayakumar</td>
<td>20</td>
<td>M</td>
<td>Fr-3 days, myalgia</td>
<td>20000</td>
<td>3100</td>
<td>41.9</td>
<td>49</td>
<td>44 GB wall thickening, RPE</td>
<td>p</td>
<td>N N pri DHF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>4144</td>
<td>Saraswathy</td>
<td>66</td>
<td>F</td>
<td>Fr-7 days, Arthralgia, myalgia</td>
<td>76000</td>
<td>3600</td>
<td>24</td>
<td>25</td>
<td>23 GB thickening</td>
<td>N</td>
<td>p P SEC DF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>5765</td>
<td>Jayamani</td>
<td>47</td>
<td>F</td>
<td>Fr-5 days, Melena, purpurahardpala tebleeding</td>
<td>50000</td>
<td>3800</td>
<td>24.6</td>
<td>30</td>
<td>31 Normal</td>
<td>p</td>
<td>N N PRI DHF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>6163</td>
<td>Samuel</td>
<td>22</td>
<td>M</td>
<td>Fr-2 days, Arthralgia</td>
<td>35000</td>
<td>3950</td>
<td>42.2</td>
<td>27</td>
<td>30 R PE</td>
<td>p</td>
<td>N N PRI DHF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>61653</td>
<td>Rajendran</td>
<td>27</td>
<td>M</td>
<td>Fr-4 days, Bleeding gums 2 days, myalgia</td>
<td>30000</td>
<td>3800</td>
<td>36.8</td>
<td>27</td>
<td>41 Normal</td>
<td>N</td>
<td>p P SEC DF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>9143</td>
<td>Haridharshini</td>
<td>4</td>
<td>fch</td>
<td>Fr, Vomiting 6 days, Oliguria</td>
<td>83000</td>
<td>2000</td>
<td>38.2</td>
<td>28</td>
<td>25 O</td>
<td>N</td>
<td>p P SEC DF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>18828</td>
<td>Ansiya</td>
<td>8</td>
<td>fch</td>
<td>Fr-11 days, Vomiting 1 day</td>
<td>53000</td>
<td>3100</td>
<td>38.8</td>
<td>29</td>
<td>22 GB thickening</td>
<td>N</td>
<td>p P SEC DHF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>ID</td>
<td>Name</td>
<td>Age</td>
<td>Gender</td>
<td>Fr. days &amp; Symptoms</td>
<td>WBC</td>
<td>Hb</td>
<td>Platelets</td>
<td>Temperature</td>
<td>P/C/D/P</td>
<td>GB Status</td>
<td>PE</td>
<td>Bil. Status</td>
<td>Bil. PE</td>
<td>Comments</td>
</tr>
<tr>
<td>-----</td>
<td>---------</td>
<td>----------</td>
<td>-----</td>
<td>--------</td>
<td>---------------------</td>
<td>-----</td>
<td>------</td>
<td>-----------</td>
<td>-------------</td>
<td>---------</td>
<td>-----------</td>
<td>----</td>
<td>-------------</td>
<td>--------</td>
<td>----------</td>
</tr>
<tr>
<td>27</td>
<td>11348</td>
<td>Nuthun</td>
<td>26</td>
<td>M</td>
<td>Fr-5 days, Vomiting, Arthralgia, Haematuria, Epitaxis</td>
<td>36000</td>
<td>2600</td>
<td>48.6</td>
<td>45</td>
<td>50</td>
<td>R minimal PE</td>
<td>P</td>
<td>N</td>
<td>N</td>
<td>PRI</td>
</tr>
<tr>
<td>28</td>
<td>11943</td>
<td>Velmurugan</td>
<td>32</td>
<td>M</td>
<td>Fr-4 days, Arthralgia, Myalgia, bleeding gums</td>
<td>39000</td>
<td>2000</td>
<td>45.7</td>
<td>22</td>
<td>24</td>
<td>Normal</td>
<td>P</td>
<td>N</td>
<td>N</td>
<td>PRI</td>
</tr>
<tr>
<td>29</td>
<td>68327</td>
<td>Irfanahmed</td>
<td>6</td>
<td>mch</td>
<td>Fr-6 days, Myalgia</td>
<td>33000</td>
<td>3910</td>
<td>36</td>
<td>25</td>
<td>26</td>
<td>Thickened GB, Bil. PE</td>
<td>N</td>
<td>P</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>30</td>
<td>72407</td>
<td>Priyanka</td>
<td>8</td>
<td>fch</td>
<td>Fr-5 days, Arthralgia</td>
<td>31000</td>
<td>3700</td>
<td>38.5</td>
<td>41</td>
<td>43</td>
<td>-</td>
<td>p</td>
<td>N</td>
<td>N</td>
<td>PRI</td>
</tr>
<tr>
<td>31</td>
<td>Anandkumar</td>
<td>14</td>
<td>M</td>
<td></td>
<td>Fr-5 days, Hematemesis, Myalgia</td>
<td>55000</td>
<td>3000</td>
<td>40</td>
<td>42</td>
<td>40</td>
<td>Normal</td>
<td>P</td>
<td>N</td>
<td>N</td>
<td>PRI</td>
</tr>
<tr>
<td>32</td>
<td>1E+05</td>
<td>Mansurali</td>
<td>24</td>
<td>M</td>
<td>Fr-7 days, Haematuria</td>
<td>66000</td>
<td>3000</td>
<td>45.5</td>
<td>35</td>
<td>30</td>
<td>GB wall thickening</td>
<td>p</td>
<td>p</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>33</td>
<td>18433</td>
<td>Sagana</td>
<td>5</td>
<td>fch</td>
<td>Fr-6 days, Myalgia</td>
<td>82000</td>
<td>6000</td>
<td>46</td>
<td>25</td>
<td>27</td>
<td>minimal R pleural effusion</td>
<td>p</td>
<td>p</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>34</td>
<td>19258</td>
<td>Bathri</td>
<td>3</td>
<td>fch</td>
<td>Fr-11 days, Edema 2 days, Hematemesis, Rash</td>
<td>48000</td>
<td>3500</td>
<td>46.4</td>
<td>20</td>
<td>25</td>
<td>GB wall thickening</td>
<td>N</td>
<td>p</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>35</td>
<td>9676</td>
<td>Karthick</td>
<td>3</td>
<td>fch</td>
<td>Fr-4 days, Abdominal Pain</td>
<td>74000</td>
<td>8000</td>
<td>48</td>
<td>58</td>
<td>55</td>
<td>diffuse GB thickening</td>
<td>p</td>
<td>N</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>36</td>
<td>20502</td>
<td>Vignesh</td>
<td>6</td>
<td>mch</td>
<td>Fr-4 days, Vomiting, Myalgia</td>
<td>28000</td>
<td>8200</td>
<td>45.8</td>
<td>26</td>
<td>21</td>
<td>minimal R PE, GB wall thickening</td>
<td>p</td>
<td>P</td>
<td>N</td>
<td>PRI</td>
</tr>
<tr>
<td>37</td>
<td>20432</td>
<td>Rahul</td>
<td>3</td>
<td>mch</td>
<td>Fr-6 days, Vomiting</td>
<td>27000</td>
<td>4900</td>
<td>37.5</td>
<td>20</td>
<td>25</td>
<td>minimal R PE, GB wall thickening</td>
<td>N</td>
<td>p</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>38</td>
<td>24426</td>
<td>Vinithkumar</td>
<td>3</td>
<td>mch</td>
<td>Fr-7 days, Abdominal Pain, Nausea, Vomiting</td>
<td>17000</td>
<td>3100</td>
<td>36</td>
<td>26</td>
<td>28</td>
<td>GB wall thickening</td>
<td>N</td>
<td>p</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>39</td>
<td>24481</td>
<td>Prahalad</td>
<td>30</td>
<td>M</td>
<td>Fr-6 days, Myalgia</td>
<td>49000</td>
<td>4000</td>
<td>48</td>
<td>43</td>
<td>47</td>
<td>Normal</td>
<td>N</td>
<td>p</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>S. No</td>
<td>ID No</td>
<td>Name</td>
<td>Age</td>
<td>Sex</td>
<td>Fr.</td>
<td>Duration</td>
<td>Symptoms</td>
<td>Lab</td>
<td>Other Findings</td>
<td>Other Findings</td>
<td>Chest X-ray</td>
<td>ECG</td>
<td>KSTU</td>
<td>DF</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>--------</td>
<td>-------</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>----------</td>
<td>----------</td>
<td>-----</td>
<td>----------------</td>
<td>----------------</td>
<td>------------</td>
<td>-----</td>
<td>------</td>
<td>----</td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>26097</td>
<td>Harichander</td>
<td>2</td>
<td>mch</td>
<td>Fr-8 days, Abdmn Pain</td>
<td>60000</td>
<td>5000</td>
<td>33</td>
<td>35</td>
<td>30</td>
<td>0</td>
<td>N</td>
<td>p</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>41</td>
<td>2E+05</td>
<td>Ashok kumar</td>
<td>17</td>
<td>M</td>
<td>Fr-8 days, arthralgia, myalgia</td>
<td>37000</td>
<td>3500</td>
<td>42</td>
<td>37</td>
<td>30</td>
<td>GB thickening</td>
<td>N</td>
<td>p</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>42</td>
<td>35207</td>
<td>Balu</td>
<td>36</td>
<td>M</td>
<td>Fr-4 days, Arthralgia</td>
<td>45000</td>
<td>3800</td>
<td>33.1</td>
<td>43</td>
<td>45</td>
<td>Hepatomegaly</td>
<td>P</td>
<td>p</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>43</td>
<td>35906</td>
<td>Ramesh</td>
<td>38</td>
<td>M</td>
<td>Fr-7 days, Vomiting 1 episode, Myalgia, bleeding gums</td>
<td>20000</td>
<td>10600</td>
<td>48.5</td>
<td>28</td>
<td>29</td>
<td>GB wall thickening</td>
<td>P</td>
<td>p</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>44</td>
<td>32911</td>
<td>Manoba</td>
<td>9</td>
<td>mch</td>
<td>Fr-5 day Abdmn Pain, Vomiting, headache, mele na</td>
<td>37000</td>
<td>8200</td>
<td>41</td>
<td>25</td>
<td>27</td>
<td>GB thickening</td>
<td>N</td>
<td>p</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>45</td>
<td>32910</td>
<td>Jeevasri</td>
<td>10</td>
<td>fch</td>
<td>Fr with Chills, Abdmn Pain 4 days, myalgia</td>
<td>31000</td>
<td>2800</td>
<td>33.7</td>
<td>29</td>
<td>25</td>
<td>Bil.PE, min.FF abdomen</td>
<td>P</td>
<td>N</td>
<td>N</td>
<td>PRI</td>
</tr>
<tr>
<td>46</td>
<td>32075</td>
<td>Meenambigai</td>
<td>6</td>
<td>fch</td>
<td>Fr-4 days, Vomiting, myalgia</td>
<td>26000</td>
<td>3200</td>
<td>37.2</td>
<td>28</td>
<td>21</td>
<td>GB wall thickened</td>
<td>P</td>
<td>p</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>47</td>
<td>7815</td>
<td>Kumaravel</td>
<td>7</td>
<td>mch</td>
<td>Fr-7 days, Vomiting, myalgia</td>
<td>49000</td>
<td>4500</td>
<td>32</td>
<td>27</td>
<td>28</td>
<td>Normal</td>
<td>N</td>
<td>P</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>48</td>
<td>7816</td>
<td>Vetrivel</td>
<td>4</td>
<td>mch</td>
<td>Fr-7 days, Abdmn pain, Vomiting</td>
<td>55000</td>
<td>3200</td>
<td>40</td>
<td>23</td>
<td>25</td>
<td>normal</td>
<td>N</td>
<td>P</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>49</td>
<td>33544</td>
<td>Arunvijay</td>
<td>15</td>
<td>M</td>
<td>Fr-11 days, abd.pain, myalgia</td>
<td>17000</td>
<td>3100</td>
<td>42</td>
<td>36</td>
<td>32</td>
<td>min.RPE, Assecites</td>
<td>N</td>
<td>P</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>50</td>
<td>35493</td>
<td>Damodaran</td>
<td>12</td>
<td>M</td>
<td>Fr-12 days, Myalgia, Arthralgia</td>
<td>129000</td>
<td>2200</td>
<td>33.6</td>
<td>27</td>
<td>24</td>
<td>Gb wall edematus</td>
<td>N</td>
<td>P</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>51</td>
<td>35095</td>
<td>Saranya</td>
<td>16</td>
<td>F</td>
<td>Fr-4 days, artralgia</td>
<td>17000</td>
<td>5700</td>
<td>32.2</td>
<td>45</td>
<td>48</td>
<td>GB edematous, Bil.PEFF abdomen &amp; pelvis</td>
<td>P</td>
<td>N</td>
<td>N</td>
<td>PRI</td>
</tr>
<tr>
<td>52</td>
<td>35184</td>
<td>sathish</td>
<td>24</td>
<td>M</td>
<td>Fr-4 days, Myalgia, Arthralgia, headache, vomiting</td>
<td>46000</td>
<td>5000</td>
<td>52.5</td>
<td>30</td>
<td>32</td>
<td>GB wall edematous</td>
<td>p</td>
<td>p</td>
<td>N</td>
<td>PRI</td>
</tr>
<tr>
<td>No.</td>
<td>ID</td>
<td>Name</td>
<td>Age</td>
<td>Gender</td>
<td>History</td>
<td>Duration</td>
<td>Temperature</td>
<td>Blood Pressure</td>
<td>Abnormalities</td>
<td>Details</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>-------</td>
<td>--------------</td>
<td>-----</td>
<td>--------</td>
<td>---------</td>
<td>----------</td>
<td>-------------</td>
<td>----------------</td>
<td>--------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>35240</td>
<td>Ashok Kumar</td>
<td>8</td>
<td>M</td>
<td>Fr-6 days, Vomiting 5 days, Melena, Abdominal Pain</td>
<td>36000 3200 33.7 35 30</td>
<td>GB wall edematous, Bil.PE, ascites</td>
<td>N p P SEC DHF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>35375</td>
<td>Valliyammal</td>
<td>60</td>
<td>F</td>
<td>Fr-5 days, Arthralgia</td>
<td>35000 7000 35 32 30</td>
<td>GB contracted</td>
<td>P N N PRI DF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>35376</td>
<td>Mohammed Hussain</td>
<td>15</td>
<td>M</td>
<td>Fr-11 days, Myalgia</td>
<td>17000 3800 50.8 45 48</td>
<td>GB thickening</td>
<td>N p P SEC DHF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>31346</td>
<td>Murugan</td>
<td>32</td>
<td>M</td>
<td>Fr-4 days, Dysuria, Headache, Arthralgia</td>
<td>61000 2600 42.5 29 30</td>
<td>-</td>
<td>P p N PRI DF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>35333</td>
<td>Navanathan</td>
<td>4 mch</td>
<td>M</td>
<td>Fr-11 days, Vomiting, Myalgia</td>
<td>45000 3500 40.2 28 30</td>
<td>GB thickened</td>
<td>N P P SEC DF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>35236</td>
<td>Selvakrishnan</td>
<td>1 mch</td>
<td>M</td>
<td>Fr-4 days, Headache</td>
<td>56000 14000 39.5 32 80</td>
<td>NA</td>
<td>p P P SEC DF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>59</td>
<td>33510</td>
<td>Logeswaran</td>
<td>19</td>
<td>M</td>
<td>Fr-7 days, Myalgia, Arthralgia</td>
<td>24000 5100 19 25 22</td>
<td>Normal</td>
<td>N p P SEC DF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>32336</td>
<td>Manikandan</td>
<td>32</td>
<td>M</td>
<td>Fr-1 weeks, Arthralgia 10 days</td>
<td>87000 3000 36 42 45</td>
<td>NA</td>
<td>N p P SEC DF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>61</td>
<td>34418</td>
<td>Shankar</td>
<td>26</td>
<td>M</td>
<td>Fr-2 days, Myalgia, Arthralgia</td>
<td>7000 3000 49.4 24 26</td>
<td>Hepatomegaly</td>
<td>p P P SEC DF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>62</td>
<td>34579</td>
<td>Sivakumar</td>
<td>20</td>
<td>M</td>
<td>Fr-12 days, Vomiting, Melena 3 days</td>
<td>14000 2900 45.6 28 30</td>
<td>minimal RPE, Ascites</td>
<td>N P P SEC DHF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>63</td>
<td>36503</td>
<td>Dharshini</td>
<td>7 fch</td>
<td>M</td>
<td>Fr-5 days, Refusal of feeds 3 days, melena 1 day</td>
<td>55000 13400 27.6 32 40</td>
<td>Hepatomegaly</td>
<td>N N P SEC DF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>64</td>
<td>36331</td>
<td>Jithin Samuel</td>
<td>10</td>
<td>mch</td>
<td>Fr-4 days, Arthralgia</td>
<td>87000 330000% 33 37 35</td>
<td>hepatomegaly, GB contracted</td>
<td>N N P SEC DF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65</td>
<td>36450</td>
<td>Divya</td>
<td>21</td>
<td>F</td>
<td>Fr-5 days, Rash, Abdominal Pain</td>
<td>88000 3600 45.9 35 32</td>
<td>GB thickened</td>
<td>P N N PRI DHF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>66</td>
<td>36394</td>
<td>Vijayaraghavan</td>
<td>1.5</td>
<td>mch</td>
<td>Fr-5 days, Abdominal Pain 4 days</td>
<td>360000 3300 48.8 42 43</td>
<td>GB contracted</td>
<td>P N N PRI DHF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>ID</td>
<td>Name</td>
<td>Gender</td>
<td>Fr.</td>
<td>Symptoms</td>
<td>Age</td>
<td>Temp</td>
<td>HR</td>
<td>RR</td>
<td>SBP</td>
<td>DBP</td>
<td>WBC</td>
<td>Platelets</td>
<td>Hb</td>
<td>HCT</td>
</tr>
<tr>
<td>-----</td>
<td>--------</td>
<td>-------</td>
<td>--------</td>
<td>-----</td>
<td>-----------------------------------</td>
<td>-----</td>
<td>-------</td>
<td>-------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>--------</td>
<td>---------</td>
<td>--------</td>
<td>-------</td>
</tr>
<tr>
<td>67</td>
<td>36436</td>
<td>Bhagyalakshmi</td>
<td>F</td>
<td>18</td>
<td>Fr-5 days, Vomiting 3 days, Abdmn pain 4 days</td>
<td>68000</td>
<td>3600</td>
<td>46.9</td>
<td>30</td>
<td>42</td>
<td>GB wall thickening</td>
<td>P</td>
<td>N</td>
<td>N</td>
<td>PRI</td>
</tr>
<tr>
<td>68</td>
<td>32482</td>
<td>Amirtha</td>
<td>F</td>
<td>17</td>
<td>Fr-10 days, arthralgia</td>
<td>200000</td>
<td>6500</td>
<td>31</td>
<td>25</td>
<td>27</td>
<td>normal</td>
<td>N</td>
<td>P</td>
<td>N</td>
<td>PRI</td>
</tr>
<tr>
<td>69</td>
<td>34794</td>
<td>Amirtham</td>
<td>F</td>
<td>40</td>
<td>Fr-5 days, arthralgia, myalgia</td>
<td>100000</td>
<td>4000</td>
<td>42</td>
<td>43</td>
<td>45</td>
<td>NA</td>
<td>P</td>
<td>N</td>
<td>N</td>
<td>PRI</td>
</tr>
<tr>
<td>70</td>
<td>35040</td>
<td>Priyadharshini</td>
<td>fch</td>
<td>12</td>
<td>Fr-5 days, arthralgia</td>
<td>111000</td>
<td>4800</td>
<td>12.7</td>
<td>25</td>
<td>27</td>
<td>hepatomegaly</td>
<td>P</td>
<td>N</td>
<td>N</td>
<td>PRI</td>
</tr>
<tr>
<td>71</td>
<td>37045</td>
<td>Deepika</td>
<td>F</td>
<td>17</td>
<td>Fr-3 days, arthralgia</td>
<td>68000</td>
<td>6200</td>
<td>22.5</td>
<td>26</td>
<td>25</td>
<td>normal</td>
<td>P</td>
<td>N</td>
<td>N</td>
<td>PRI</td>
</tr>
<tr>
<td>72</td>
<td>33204</td>
<td>Kelvin</td>
<td>M</td>
<td>46</td>
<td>Fr, Abdmn pain 3 days, myalgia</td>
<td>70000</td>
<td>2500</td>
<td>32</td>
<td>23</td>
<td>25</td>
<td>-</td>
<td>p</td>
<td>N</td>
<td>N</td>
<td>PRI</td>
</tr>
<tr>
<td>73</td>
<td>35331</td>
<td>AyishaRithiga</td>
<td>F</td>
<td>23</td>
<td>Fr-3 days, Arthralgia</td>
<td>100000</td>
<td>1500</td>
<td>12.7</td>
<td>25</td>
<td>25</td>
<td>Normal</td>
<td>P</td>
<td>N</td>
<td>N</td>
<td>PRI</td>
</tr>
<tr>
<td>74</td>
<td>34531</td>
<td>Munna</td>
<td>M</td>
<td>23</td>
<td>Fr-6 days, vomiting, abdmn pain, arthralgia</td>
<td>16000</td>
<td>6300</td>
<td>33.7</td>
<td>29</td>
<td>27</td>
<td>Normal</td>
<td>N</td>
<td>N</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>75</td>
<td>2E+05</td>
<td>Dharshan</td>
<td>mch</td>
<td>1</td>
<td>Fr-5 days, Abdmn pain, hemetemesis</td>
<td>65000</td>
<td>2500</td>
<td>47</td>
<td>50</td>
<td>53</td>
<td>GB thickening, pleural effusion, ascites.</td>
<td>p</td>
<td>N</td>
<td>p</td>
<td>SEC</td>
</tr>
<tr>
<td>76</td>
<td>78957</td>
<td>Kamala</td>
<td>F</td>
<td>22</td>
<td>Fr-10 days, Myalgia</td>
<td>27000</td>
<td>3400</td>
<td>32.8</td>
<td>26</td>
<td>21</td>
<td>Normal</td>
<td>N</td>
<td>P</td>
<td>N</td>
<td>PRI</td>
</tr>
<tr>
<td>77</td>
<td>73621</td>
<td>Amudhavalli</td>
<td>F</td>
<td>22</td>
<td>Fr-3 days, Myalgia, Arthralgia</td>
<td>13200</td>
<td>4800</td>
<td>36.9</td>
<td>25</td>
<td>28</td>
<td>NA</td>
<td>P</td>
<td>p</td>
<td>P</td>
<td>SEC</td>
</tr>
<tr>
<td>78</td>
<td>72846</td>
<td>Yamuna</td>
<td>fch</td>
<td>6</td>
<td>Fr-5 days, vomiting</td>
<td>113000</td>
<td>5600</td>
<td>28</td>
<td>24</td>
<td>26</td>
<td>XR PE</td>
<td>p</td>
<td>P</td>
<td>N</td>
<td>PRI</td>
</tr>
<tr>
<td>79</td>
<td>7973</td>
<td>Aravivel</td>
<td>mch</td>
<td>12</td>
<td>Fr-5 days, Myalgia, Abdmn pain, Melena</td>
<td>45000</td>
<td>6000</td>
<td>34</td>
<td>42</td>
<td>43</td>
<td>GB thickening</td>
<td>N</td>
<td>p</td>
<td>p</td>
<td>SEC</td>
</tr>
<tr>
<td>80</td>
<td>7862</td>
<td>Kalingaraj</td>
<td>M</td>
<td>13</td>
<td>Fr-7 days, vomiting</td>
<td>39000</td>
<td>2400</td>
<td>46.6</td>
<td>35</td>
<td>37</td>
<td>GB thickening</td>
<td>N</td>
<td>p</td>
<td>p</td>
<td>PRI</td>
</tr>
<tr>
<td>No.</td>
<td>ID</td>
<td>Name</td>
<td>Age</td>
<td>Gender</td>
<td>Fr.</td>
<td>Symptoms</td>
<td>WBC</td>
<td>Hb</td>
<td>Platelets</td>
<td>Temperature</td>
<td>Blood Pressure</td>
<td>Labs</td>
<td>Other Findings</td>
<td>Outcome</td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>-------</td>
<td>----------</td>
<td>-----</td>
<td>--------</td>
<td>-----</td>
<td>------------------------------</td>
<td>-----</td>
<td>------</td>
<td>-----------</td>
<td>-------------</td>
<td>----------------</td>
<td>------</td>
<td>----------------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>81</td>
<td>70488</td>
<td>Jaya</td>
<td>21</td>
<td>F</td>
<td>Fr-3 days</td>
<td>Fr-6 days, Myalgia, Nausea, Vomiting</td>
<td>63000</td>
<td>1700</td>
<td>38.5</td>
<td>32</td>
<td>39</td>
<td>Normal</td>
<td>N p N</td>
<td>PRI</td>
<td></td>
</tr>
<tr>
<td>82</td>
<td>7389</td>
<td>Mani</td>
<td>34</td>
<td>M</td>
<td>Fr-6 days</td>
<td>Fr-6 days, Myalgia, Nausea, Vomiting</td>
<td>14000</td>
<td>3000</td>
<td>35</td>
<td>29</td>
<td>27</td>
<td>-</td>
<td>N p P</td>
<td>PRI</td>
<td></td>
</tr>
<tr>
<td>83</td>
<td>23275</td>
<td>Nitesesh</td>
<td>6</td>
<td>mch</td>
<td>Fr-10 days</td>
<td>Myalgia, Nausea, Vomiting</td>
<td>94000</td>
<td>6000</td>
<td>36</td>
<td>28</td>
<td>29</td>
<td>-</td>
<td>N p N</td>
<td>PRI</td>
<td></td>
</tr>
<tr>
<td>84</td>
<td>71821</td>
<td>Dinakaran</td>
<td>8</td>
<td>mch</td>
<td>Fr-15 days</td>
<td>Fr-15 days, Abdominal Pain</td>
<td>190,000</td>
<td>9800</td>
<td>30</td>
<td>25</td>
<td>27</td>
<td>Normal</td>
<td>N p P</td>
<td>PRI</td>
<td></td>
</tr>
<tr>
<td>85</td>
<td>62920</td>
<td>Poongodi</td>
<td>7</td>
<td>fch</td>
<td>Fr-5 days</td>
<td>Fr-5 days, Abdominal Pain</td>
<td>82000</td>
<td>2300</td>
<td>38.6</td>
<td>27</td>
<td>29</td>
<td>Normal</td>
<td>P N N</td>
<td>PRI</td>
<td></td>
</tr>
<tr>
<td>86</td>
<td>7288</td>
<td>Maheswari</td>
<td>10</td>
<td>fch</td>
<td>Fr-3 days</td>
<td>Fr-3 days, Myalgia</td>
<td>70000</td>
<td>3000</td>
<td>49.7</td>
<td>28</td>
<td>30</td>
<td>hepatomegaly, PE</td>
<td>P p N</td>
<td>PRI DHF</td>
<td></td>
</tr>
<tr>
<td>87</td>
<td>32266</td>
<td>Lakshmanan Babu</td>
<td>8</td>
<td>mch</td>
<td>Fr-5 days</td>
<td>Fr-5 days</td>
<td>52000</td>
<td>2000</td>
<td>39</td>
<td>29</td>
<td>30</td>
<td>Normal</td>
<td>P N N</td>
<td>PRI</td>
<td></td>
</tr>
<tr>
<td>88</td>
<td>7173</td>
<td>Umadevi</td>
<td>9</td>
<td>fch</td>
<td>Fr-3 days</td>
<td>Fr-3 days, Melena 1 day, Oliguria 2 days</td>
<td>34000</td>
<td>1700</td>
<td>48</td>
<td>25</td>
<td>27</td>
<td>FF abdomen</td>
<td>P p P</td>
<td>SEC DHF</td>
<td></td>
</tr>
<tr>
<td>89</td>
<td>31102</td>
<td>Priya</td>
<td>23</td>
<td>F</td>
<td>Fr-3 days</td>
<td>Fr-3 days</td>
<td>36000</td>
<td>3000</td>
<td>35</td>
<td>28</td>
<td>30</td>
<td>-</td>
<td>P N N</td>
<td>PRI</td>
<td></td>
</tr>
<tr>
<td>90</td>
<td>28551</td>
<td>Lalitha</td>
<td>15</td>
<td>F</td>
<td>Fr-5 days</td>
<td>Fr-5 days</td>
<td>72,000</td>
<td>2000</td>
<td>38</td>
<td>25</td>
<td>27</td>
<td>Normal</td>
<td>P N N</td>
<td>PRI</td>
<td></td>
</tr>
<tr>
<td>91</td>
<td>32394</td>
<td>Sathish Kumar</td>
<td>38</td>
<td>M</td>
<td>Fr-5 days</td>
<td>Fr-5 days, Vomiting</td>
<td>60000</td>
<td>5200</td>
<td>46</td>
<td>30</td>
<td>42</td>
<td>minimal R PE</td>
<td>P N N</td>
<td>PRI DHF</td>
<td></td>
</tr>
<tr>
<td>92</td>
<td>67696</td>
<td>Sikinder</td>
<td>35</td>
<td>M</td>
<td>Fr-5 days</td>
<td>Fr-5 days, Abdominal Pain 2 days, Arthralgia</td>
<td>37000</td>
<td>3000</td>
<td>29.4</td>
<td>25</td>
<td>27</td>
<td>Normal</td>
<td>P p N</td>
<td>PRI</td>
<td></td>
</tr>
<tr>
<td>93</td>
<td>68299</td>
<td>Indurekha</td>
<td>13</td>
<td>F</td>
<td>Fr-3 days</td>
<td>Fr-3 days, Arthralgia</td>
<td>57,000</td>
<td>7000</td>
<td>30</td>
<td>33</td>
<td>35</td>
<td>-</td>
<td>P p N</td>
<td>PRI</td>
<td></td>
</tr>
<tr>
<td>94</td>
<td>71223</td>
<td>Venkatprabu</td>
<td>8.12</td>
<td>mch</td>
<td>Fr-7 days</td>
<td>Fr-7 days, Melena 2 days, Abdominal pain</td>
<td>29000</td>
<td>3000</td>
<td>45.3</td>
<td>25</td>
<td>29</td>
<td>bil.PE</td>
<td>N p N</td>
<td>PRI</td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>Code</td>
<td>Name</td>
<td>Age</td>
<td>Gender</td>
<td>Disease Duration</td>
<td>Symptoms</td>
<td>Serum creatinine</td>
<td>Bilirubin</td>
<td>Albumin</td>
<td>Temperature</td>
<td>Other</td>
<td>Notes</td>
<td>Diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>--------</td>
<td>---------------</td>
<td>------</td>
<td>--------</td>
<td>-----------------</td>
<td>---------------------------------------------------------------------------</td>
<td>------------------</td>
<td>-----------</td>
<td>---------</td>
<td>-------------</td>
<td>---------</td>
<td>-------</td>
<td>------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>3320</td>
<td>Gopalakrishnan</td>
<td>10 mch</td>
<td></td>
<td>Fr-5 days, Vomiting 3 days, Melena 3 days</td>
<td>73000 3000 35 27 29</td>
<td>ascites</td>
<td>P N N</td>
<td>PRI DHF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>31647</td>
<td>Venkatachalam</td>
<td>30 M</td>
<td></td>
<td>Fr-4 days, Abdmn Pain, Giddiness, arthralgia</td>
<td>15000 3000 40 29 30</td>
<td>-</td>
<td>P   N</td>
<td>PRI DF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>97</td>
<td>30889</td>
<td>Bharath</td>
<td>10 mch</td>
<td></td>
<td>Fr-5 days, Abdmn Pain, Melena</td>
<td>80000 3800 46 27 29</td>
<td>pleural effusion</td>
<td>P   p</td>
<td>SEC DHF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>98</td>
<td>3E+05</td>
<td>Karthick</td>
<td>11 M</td>
<td></td>
<td>Fever 5 days, Headache 5 day, Melena 4 days, Abdmn Pain</td>
<td>32000 2600 37.5 30 35</td>
<td>bil. PE</td>
<td>P   p</td>
<td>SEC DHF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>31346</td>
<td>Murugesan</td>
<td>32 M</td>
<td></td>
<td>Fr-6 days, Abdmn Pain, Dysuria 4 days</td>
<td>61000 2600 45.5 31 35</td>
<td>pleural effusion</td>
<td>N   p</td>
<td>N PRI DHF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>31344</td>
<td>Ashok</td>
<td>10 mch</td>
<td></td>
<td>Fr-4 days, Vomiting, Poor appetite, Myalgia, Abdmn pain</td>
<td>35000 3100 57.3 32 30</td>
<td>ascites</td>
<td>P N N</td>
<td>PRI DHF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>101</td>
<td>33233</td>
<td>Kaviraj</td>
<td>16 M</td>
<td></td>
<td>Fr-7 days Abdmn pain, arthralgia</td>
<td>73000 2700 42 20 25</td>
<td>pleural effusion</td>
<td>N   p</td>
<td>P PRI DHF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>102</td>
<td>34282</td>
<td>Dilfar</td>
<td>5 mch</td>
<td></td>
<td>Fr-7 days, Vomiting 2 days</td>
<td>22000 3500 46.5 25 27</td>
<td>minimal R PE</td>
<td>N   p</td>
<td>N PRI DHF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>103</td>
<td>28819</td>
<td>sakthivel</td>
<td>27 M</td>
<td></td>
<td>Fr-6 days, Myalgia</td>
<td>48000 2900 39 23 25</td>
<td>-</td>
<td>N   p</td>
<td>N PRI DF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>104</td>
<td>33367</td>
<td>Amritha Iniya</td>
<td>7 fch</td>
<td></td>
<td>Fr-3 days, Vomiting, Abdmn pain</td>
<td>21000 5600 39.8 43 47</td>
<td>ascites</td>
<td>N N   P</td>
<td>SEC DHF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>105</td>
<td>33739</td>
<td>Thangomani</td>
<td>40 F</td>
<td></td>
<td>Fr-2 days, Burning Micturition, Myalgia</td>
<td>31000 2400 36 25 24</td>
<td>normal</td>
<td>p   p</td>
<td>N PRI DF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>106</td>
<td>33755</td>
<td>Subramani</td>
<td>62 M</td>
<td></td>
<td>Fr-12 days, Myalgia</td>
<td>57000 3000 33 25 27</td>
<td>normal</td>
<td>N   P</td>
<td>P SEC DF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>107</td>
<td>33855</td>
<td>Navaneetha Krishnan</td>
<td>12 mch</td>
<td></td>
<td>Fr-5 days, Myalgia, Abdmn pain, Melena</td>
<td>28000 3500 48 29 30</td>
<td>ascites</td>
<td>N N   P</td>
<td>SEC DHF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: P-Positive, N - Negative, M-Male, F-Female, mch-MaleChild, fch-FemaleChild
Multivariate Analysis of Dengue in a Tertiary Care Hospital.

ABSTRACT

Background: Dengue is a viral infection with potential fatal complications. It is considered as one of the worlds major emerging tropical diseases. More than 2.5 billion people are at risk of infection and more than 100 countries have endemic transmission. The emergence and reemergence of dengue is attributed to demographic and societal changes with increased movement of people from endemic areas and inadequate mosquito control measures. It is an emerging disease in Tamilnadu. Dengue virus is an enveloped ssRNA virus of 45-50 nm belonging to Genus flavivirus and Family flaviviridae. Dengue is transmitted by Aedes aegypti mosquitoes. It causes wide spectrum of illness ranging from undifferentiated illness to Dengue haemorrhagic fever and Dengue shock syndrome. Specific IgM and IgG detection has been the mainstay of diagnosis for a long time. Dengue specific antigen is found to be highly specific and reliable marker from the first day of diagnosis. Aim and objectives: To study the multivariate analysis of Dengue with serological differentiation of primary(PD) and secondary dengue(SD), comparative evaluation of Immunochromatography(ICT) with Immunocapture Enzyme Linked Immuno Sorbent Assay (ELISA) and special emphasis on Nonstructural protein( NS1) antigen as an early diagnostic marker . To correlate Dengue clinically with haematological and biochemical profile. Materials and methods: After taking informed consent, blood was drawn from three hundred and fifty suspected cases and were subjected to both ICT and ELISA.ELISA positive cases were analysed further. Accuracy indices of ICT were calculated using ELISA as reference assay. Results: Out of 350 samples tested ,107 were positive by ELISA (30.5%) for one or more serological markers. The common age group affected were 0-10 years in both sexes with male: female ratio of 1.6:1.Incidence was high during November to December 2011& January , May
June & July 2012. Clinically seropositives were classified as Dengue fever, Dengue haemorrhagic fever and Dengue shock syndrome. There was significant association of thrombocytopenia, HCT and WBC count with Dengue fever, DHF and DSS. The 107 seropositives by ELISA were categorized as primary and secondary dengue based on duration of fever and serological markers. Out of 107, 27 were positive for NS1 only, 9 were positive for IgM alone, only 6 showed IgG alone. More than one marker was detected in the remaining 65 samples. In 48 primary dengue cases NS1 had higher positivity and in secondary dengue IgM & IgG ratio >1 had higher positivity. Sensitivity, specificity, PPV and NPV of the ICT were calculated using ELISA as reference for individual markers which showed moderate performance. Haematological and biochemical profile also showed statistical significance in association with Dengue fever, DHF and DSS. Conclusion: Inclusion of NS1 in the routine diagnosis of dengue increases the detection rate of cases significantly in the early period. Irrespective of fever duration, all the three ELISA must be done to rule out Dengue infection like NS1, IgM, and IgG. Immunocapture ELISA is reliable and sensitive than ICT even though it is highly specific. Haematological and biochemical tests should also be given importance along with serological markers for dengue diagnosis and management.

Keywords: Dengue, NS1, PD, SD, ICT, Immunocapture ELISA.